



A BIOCHEMICAL ASSESSMENT OF STRESS 
RESPONSE FOLLOWING ACUTE AND PROLONGED 
EXPOSURE TO ANTIRETROVIRAL DRUGS 
(NUCLEOSIDE REVERSE TRANSCRIPTASE 




BMedSci (Hons) Medical Biochemistry 
Master of Medical Science 
 
Submitted in the fulfilment of the degree Doctor of Philosophy (Medical 
Biochemistry), School of Laboratory Medicine and Medical Sciences, College 








I, Savania Nagiah, declare that: 
i) The research reported in this thesis (unless otherwise indicated) is my original work, has 
not been submitted for any degree or examination at any other university, does not 
contain other persons’ data, diagrams, graphs, or other information, unless specifically 
being acknowledged as sourced from other persons, does not contain other persons’ 
writings unless being acknowledged as being sourced from other researchers. Where 
other written sources have been quoted then: 
 
a) Their work has been re-written but the information sourced has been referenced 
to the authors 
b) Where their exact words have been used, their writing has been placed within 
quotation marks and referenced 
 
ii) Where I have reproduced a publication of which I am author, co-author, or editor, I have 
indicated in detail which part of the publication was written by myself alone and have 
properly referenced such publication 
 
iii) This thesis does not contain text, graphics or tables copied and pasted from the internet, 






                            02/03/16 






To my grandfather, the late Mr T. M. Naidu. All I have learnt of spirituality, the pursuit of knowledge, 
humility, righteousness and unconditional love has stemmed from the example set by you. Without 






Prof Anil Chuturgoon 
You have been one of the greatest influences in my young adult life. Thank you for seeing potential in 
me long before I could recognise it myself. You have been far more than a mentor to me. I will 
always be grateful to you for your guidance, encouragement during difficult times and never allowing 
me to lose sight of my own worth. Thank you for all the opportunities you have provided me with 
over the past five years and I can only hope that I make you proud of the researcher and person I am 
becoming. 
Dr Alisa Phulukdaree 
You have been a mentor and a friend to me and I cannot thank you enough for your selfless nature 
when it comes to teaching. You are truly an inspiration to all the young scientists you come in contact 
with.  Thank you for being tough on me when I needed it, believing in me and encouraging me to do 
better. 
My parents and family 
Thank you for allowing me the opportunity to pursue my post-graduate studies and being 
understanding and patient with me. Your unconditional support, even in the most trying of times, 
never wavered.  You instilled the value of education in me since an early age and it is this ideal that I 
have carried throughout my years at university.  
My friends 
Miss Prithiksha Ramkaran, Miss Yashodani Pillay and Miss Nikita Naicker for the stimulating 
conversations, technical assistance, advice and laughs. You have kept me motivated and have always 
been willing to help. To Mr Noveshan Pillay, thank you for your patience, and keeping me fed/sane 
over the duration of my PhD. All of you have kept me in check and made sure I wasn’t “all work” and 
“no play”. 
Department of Medical Biochemistry (2012-2015) 
I could not have asked for a better environment in which to complete my PhD. To be surrounded by 
these buzzing academics made every day at the lab a pleasure. I must express my gratitude to the 
technical staff and students at our department for providing a family away from home. Your 





1) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. (2015). Mitochondrial and oxidative stress 
response in HepG2 cells following acute and prolonged exposure to antiretroviral drugs. 
Journal of Cellular Biochemistry 116(9), 1939-1946 
DOI (10.1002/jcb25149) 
 
2) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. (2015). Lon protease and eIF2α kinase are 
involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. 
Chemico-Biological Interactions. 
Manuscript no. CHEMBIOINT-D-15-00674 – Accepted manuscript 
 
3) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. (2015). Inverse association between 
microRNA-124a and ABCC4 in HepG2 cells treated with antiretroviral drugs. Xenobiotica – 








1) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. The effect of nucleoside reverse transcriptase 
inhibitor (NRTIs) on mitochondrial integrity and Nrf2-mediated antioxidant response in 
HepG2 cells. College of Health Science Research Symposium 2014 – University of KwaZulu 
Natal – K-RITH Towers, Durban. 11-12 September 2014. 
 
2) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. Mitochondrial and oxidative stress response 
in HepG2 cells following exposure to antiretroviral drugs for 24 and 120 hours. 9th 
International Conference of Society of Free Radical Research – Africa/4th International 
Conference of Medical and Biomedical Researchers 2015 – Mauritius. Translational Science 
and Drug Discovery 
 
3) Nagiah, S., Phulukdaree, A., Chuturgoon, A. A. Differential regulation of ABCC4 by 
microRNA-124a in HepG2 cells exposed to antiretroviral drugs. College of Health Science 











Publications………………………………………………………………………………………..….. v  
Presentations…………………………………………………………………………………………...vi 
List of Figures…………………………………………………………………………………………..x 
List of Tables………………………………………………………………………………………... xiv 
Abbreviations………………………………………………………………………………………... xv 
Abstract……………………………………………………………………………………………… xx 
Chapter one: Introduction…………………………………………………………………………... 1 
Chapter two: Literature Review 
 2.1. Human Immuno-deficiency Virus 
  2.1.1. HIV morphology………………………………………………………………. 5 
  2.1.2. Viral Replication………………………………………………………………. 6 
 2.2. Highly active antiretroviral therapy (HAART) 
  2.2.1. Nucleoside reverse transcriptase inhibitors…………………………………… 8 
  2.2.2. Non-nucleoside reverse transcriptase inhibitors………………………………. 9 
  2.2.3. Protease inhibitors……………………………………………………………. 10 
  2.2.4. Entry inhibitors 
   2.2.4.1. CCR5 antagonists…………………………………………………. 10 
   2.2.4.2. Fusion inhibitors…………………………………………………... 11 
  2.2.5. Integrase inhibitors…………………………………………………………... 11 
2.3. Antiretroviral drugs and adverse health outcomes 
viii 
 
 2.3.1. Clinical outcomes 
  2.3.1.1. Lipodystrophy……………………………………………………... 11 
  2.3.1.2. Hepatic steatosis…………………………………………………... 12 
  2.3.1.3. Hyperlactatemia…………………………………………………… 12 
 2.3.2. Biochemical outcomes 
  2.3.2.1. Mitochondrial toxicity…………………………………………….. 13 
  2.3.2.2. DNA polymerase gamma hypothesis……………………………... 14 
  2.3.2.3. Mitochondrial biogenesis…………………………………………. 15 
  2.3.2.4. Mitochondrial free radical production…………………………….. 16 
  2.3.2.5. Oxidative stress……………………………………………………. 18 
  2.3.2.6. Oxidative DNA damage…………………………………………... 18 
  2.3.2.7. Lipid peroxidation………………………………………………… 19 
  2.3.2.8. Oxidative protein damage…………………………………………. 20 
2.4. Mitochondrial protein quality surveillance 
  2.4.1. Lon protease…………………………………………………………. 21 
  2.4.2. Post-translational regulation of Lon – Sirtuin 3…………………….. 22 
  2.4.3. Lon protease and endoplasmic reticulum stress…………………….. 23 
2.5. Endogenous antioxidant defence mechanism 
  2.5.1. Superoxide detoxification…………………………………………… 25 
  2.5.2. Glutathione antioxidant defence…………………………………….. 26 
2.5.3. Master regulator of antioxidant response - Nuclear factor erythroid 2-
related factor 2 (Nrf2)……………………………………………………… 26 
2.6. Detoxification by ATP-dependent efflux drug transporters 
  2.6.1. ATP-binding cassette family of transporters………………………... 28 
   2.6.2. Multi-drug resistance proteins………………………………………. 28 
2.6.3. Multi-drug resistance protein 4 (ABCC4)…………………………… 29 
ix 
 
2.6.4. MicroRNA and drug transporters……………………………………………. 29 
 2.7. References………………………………………………………………………………. 32 
Chapter three: Mitochondrial and oxidative stress response in HepG2 cells following acute and 
  prolonged exposure to antiretroviral drugs…………………………………………. 48 
Chapter four: Lon protease and eiF2α kinase are involved in acute, but not prolonged, antiretroviral 
induced stress response in HepG2 cells…………………………………………….. 66 
Chapter five: The differential expression of microRNA-124a and ABCC4 in HepG2 cells 
following acute and prolonged exposure to antiretroviral drugs……………. 78 
Chapter six: Conclusion…………………………………………………………………... 92 
 
Appendix A…..……………………………………………………………………………... 95 
Appendix B…..……………………………………………………………………………... 97 
Appendix C……..………….……………………………………………………………….. 98 
Appendix D……………………………...………………………………………………….. 99 








LIST OF FIGURES 
Figure 2.1 Diagram of HIV mature virion. The lipid bi-layer is derived from the host 
cell. The structural proteins forming the core are matrix protein (p17), capsid 
protein (p24), and nucleocapsid (p7). The capsid contains the two strands of 
viral DNA and viral enzymes including reverse transcriptase (Karlsson 







Figure 2.2 Viral replication of HIV-1 (Ganser-Pornillos, Yeager et al. 2008)…………. 
 
7 
Figure 2.3 Ribbon representation of reverse transcriptase (RT) complex with NNRTI. 
Red represents viral subunit p66 and blue indicates subunit p51. Image 






Figure 2.4 Mechanism by which NRTI-associated mitochondrial toxicity causes lactic 
acidosis (Figure by author)…………………………………………………. 
 
13 
Figure 2.5 Schematic representation of physiological functions of mitochondria 
(adapted from Apostolova, Blas-García et al. 2011). Mitochondrial toxicants, 
such as NRTIs, can have far reaching consequences as mitochondrial 






Figure 2.6 Schematic representation of clinical outcomes in NRTI-associated mt 
toxicity. Individual ARVs display tissue specific toxicity. AZT: Zidovudine; 







Figure 2.7 The electron transport chain is the site of oxidative phosphorylation that 
drives ATP synthesis. Complex I and III have been identified as sites of 





Figure 2.8 The most physiologically abundant reactive oxygen species (Sies 1994)…... 
 
18 
Figure 2.9 Oxidized guanine (black) and adenosine (blue) adducts. Substrates for 






Figure 2.10 Schematic representation of mechanism of AAA+ protease activity. 
Recognition of unfolded/damages proteins by a peptide tag facilitates 
binding of the substrate to the protease. ATP-dependent unfolding enables 
the substrate to enter the degradation chamber (pink). Proteolysis occurs 
when ATP binds to the AAA+ module. Larger fragments may require 










Figure 2.11 Molecular mechanisms of endoplasmic reticulum mediated unfolded protein 
response. The PERK mediated response is an effort to reduce translation by 
phosphorylation of eukaryotic translation initiation factor 2α (eIF2α). 
Activating transcription factor 6 (ATF6) accelerates folding and packaging 
of proteins in the Golgi apparatus. Inositol-requiring enzyme (IRE1) 
enhances degradation of mRNA and activates stress protein c-Jun N-terminal 
kinase (JNK) and inflammatory nuclear factor kappa-light chain enhancer of 
activated B cells (NFκB). The activation of JNK amplifies the activity of 











Figure 2.12 Schematic representation of the first line of defence against mitochondrial 
ROS production. Superoxide dismutase (SOD) catalyzes the reaction of O2•- 
to H2O2. Hydrogen peroxide may be further processed by catalase (CAT) or 
glutathione peroxidase (GPx). Glutathione peroxidase mediates the donation 
of electrons from reduced glutathione (GSH) to convert H2O2 to H2O. 
Oxidized GSH (GSSG) may be converted back to the reduced state by 









Figure 2.13 The initiation of antioxidant stress response by Nrf2. Upon oxidation of 
cysteine residues binding the Nrf2/Keap1 complex, Nrf2 translocates to the 
nucleus and forms a homodimer with a small Maf protein. Following 
recognition of a consensus sequence, the Nrf2/Maf complex binds to the 
ARE and induces the transcription of antioxidant defence and transporter 
genes. Under normal conditions, Nrf2 is marked for degradation by the 















Figure 3.1 Intracellular reactive oxygen species measured as DCF fluorescence (A), 
extracellular malondialdehyde levels (B), GSH (C) and total glutathione 
(GSH+GSSG; D) in HepG2 cells treated with NRTIs at 24 h and 120 h, *p < 





Figure 3.2 ATP levels (A) and mitochondrial (mt) depolarisation (B) in HepG2 cells 
treated with zidovudine (AZT), stavudine (d4t) and tenofovir (TFV) at 24 h 







Figure 3.3 Densitometry analysis and western blot images for antioxidant and 
mitochondrial oxidative stress response protein expression at 24 h and 120 h 





Figure 4.1 Relative band intensity reported as fold change relative to control and 
western blot images for protein expression of Lon, HSP60 and SIRT3 
following acute (24 h) treatment with antiretroviral drugs. ***p < 0.0001 





Figure 4.2 Protein expression reported as relative fold change and western blot images 
for Lon, HSP60 and SIRT3 following 120 h exposure to antiretroviral drugs. 





Figure 4.3 Densitometric analysis and western blot images of endoplasmic reticulum 
stress associated proteins in HepG2 cells following 24 h exposure to 
antiretroviral drugs. Results are normalized against β-Actin and reported as 






Figure 4.4 Protein expression of endoplasmic reticulum stress associated proteins in 
HepG2 cells reported as fold change following 120 h exposure to 




Figure 5.1 Quantitative PCR analysis of miR-124a levels in HepG2 cells following 
exposure to antiretroviral drugs or 24 h (A) and 120 h (B). MicroRNA-124a 
levels are expressed in percentage (%) relative to control (100%; *p < 0.05, 







Figure 5.2 Quantitative PCR analysis of ABBC4 mRNA levels at 24 h (A) and 120 h 
(B) in HepG2 treated with antiretroviral drugs. ABBC4 mRNA is 
represented as a percentage relative to untreated control (*p < 0.05; ***p < 





Figure 5.3 Densitometric analysis of western blot for MRP4 protein at 24 h (A) and 120 




Figure 5.4 Extracellular LDH levels used as an indicator of cytotoxicity was 
significantly increased in NRTI treated cells at both 24 h (A) and 120 h (B); 











Addendum A Figure 2: Annexin-V-Fluos data for phosphatidyl-serine externalisation in 




Addendum B Figure 1: LonP1 gene expression in HepG2 cells following 24 h (A) and 




Addendum D Figure 1: Densitometric analysis of phosphorylated SIRT1 protein 




Addendum D Figure 2: Densitometric analysis of phosphorylated p53 (Ser392) protein 









Addendum E Figure 1: FACS analysis of DCF positive stained cells. At 24 h AZT (B) 
and TFV (D) had increased levels of intracellular ROS relative 







LIST OF TABLES 
 
Table 2.1 List of FDA approved NRTIs used in HAART (WHO 2010)………………… 
 
8 
Table 2.2 List of FDA approved Protease Inhibitors for HIV treatment (WHO 2010)….. 
 
10 
Table 3.1 Percentage regulation analysis of mRNA expression (OGG1; TFAM) and 
mtDNA amplification relative to untreated control at 24 h and 120 h 









Δψm    Mitochondrial membrane depolarisation 
3TC   Lamivudine 
8-oxoG   Guanine 8-oxo-7,8-dihydroguanine 
AAA+   ATPases-associated with diverse cellular activities 
ABC   Abacavir/ATP-binding cassette 
ABCC4  ATP-binding cassette C 4 
ADME   Absorption, distribution, metabolism, excretion 
ADP   Adenine diphosphate 
AIDS   Acquired Immuno-Deficiency Syndrome 
AO   Antioxidant 
APV   Amprenavir 
ARE   Antioxidant response element 
ARV   Antiretroviral 
ATF6   Activating transcription factor 6 
ATP   Adenine triphosphate 
ATPase   Adenosine triphosphatase 
ATZ   Atazanavir 
AZT   Zidovudine 
BSA   Bovine serum albumin 
bZIP   Basic region leucine zipper 
CA   Capsid 
CAT   Catalase 
CDC   Centre for Disease Control 
cDNA   Complementary DNA 
CHOP   CCAAT-enhancer-binding homologous protein 
CYP   Cytochrome P 
d4T   Stavudine 
DCF   2',7'-dichlorofluorescein 
ddC   Zalcitabine 
ddI   Didanosine 
xvi 
 
DNA   Deoxyribose nucleic acid 
DNA pol ɣ  DNA polymerase gamma 
eiF2α   Eukaryotic translation initiation factor  2 alpha 
Env   Envelope 
ER   Endoplasmic reticulum 
ETC   Electron transport chain 
ETV   Entecavir 
EVG   Emtricitabine 
FACS   Fluorescence activated cell sorting 
FDA   Food and Drug Administration 
GAPDH  Glyceraldehyde-3-Phosphate Dehydrogenase 
gp   Glycoprotein 
GPx   Glutathione peroxidase 
GR   Glutathione reductase 
GSH   Reduced glutathione 
GSSG   Oxidized glutathione 
H2DCF-D  2’,7’-dichlorodihydrofluorescein 
H2DCF-DA  dichlorodihydrofluorescein diacetate 
H2O2   Hydrogen peroxide 
HAART  Highly active antiretroviral therapy 
HepG2   Human hepatoma 
HIV   Human Immuno-deficiency Virus 
HO-1   Heme-oxygenase 1 
HRP   Horse-radish peroxidase 
HSP   Heat shock protein 
IDV   Indinavir 
IN   Integrase 
IRE-1   Inositol-requiring enzyme 1 
JNK   c-Jun N-terminal kinase 
LDH   Lactate dehydrogenase 
Lon   Lon protease 
LPV   Lopinavir 
xvii 
 
MA   Matrix 
MDA   Malondialdehyde 
miR-124a  MicroRNA-124a 
miRNA   MicroRNA 
mt   Mitochondrial 
mtDNA  Mitochondrial DNA 
MRP   Multi-drug resistance protein 
NAD+   Nicotinamide adenine dinucleotide (oxidized) 
NADH   Nicotinamide adenine dinucleotide 
NBD   Nucleotide binding domain 
NC   Nucleocapsid 
Nef   Negative factor 
NFDM   Non-fat dry milk 
NFV   Nelfinavir 
NNRTI   Non-nucleoside reverse transcriptase inhibitor 
NRF1/2  Nuclear respiratory factor 1/2 
Nrf2   Nuclear erythroid 2 related factor 2 
NRTI   Nucleoside/nucleotide reverse transcriptase inhibitor 
O2   Oxygen 
O2•-   Superoxide anion 
OD   Optical density 
OGG1   8-oxoG glycosylase 
OH•   Hydroxyl radical 
OH2•   Hydroperoxyl radical 
ORF   Open reading frame 
OXPHOS  Oxidative phosphorylation 
PBS   Phosphate saline buffer 
PCR   Polymerase chain reaction 
PERK   Protein kinase RNA-like endoplasmic reticulum kinase 
PGC-1α  Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PI   Protease inhibitor 
pol   Polymerase 
xviii 
 
PR   Protease 
Pri-miRNA  Primary transcript microRNA 
qPCR   Quantitative polymerase chain reaction 
RBI   Relative band intensity 
Rev   Regulator of expression of virion proteins 
RISC   RNA-induced silencing complex 
RLU   Relative light units 
RNA   Ribose nucleic acid 
ROS   Reactive oxygen species 
RT   Reverse transcriptase 
RTV   Ritonavir 
SDS   Sodium dodecyl sulphate 
SIRT   Sirtuin 
SQV   Saquinavir 
SOD   Superoxide dismutase 
Tat   Trans-activator of transcription 
TBARS  Thiobarbituric reactive substances 
TCA   Tricarboxylic acid 
TCEP   Tris-(2-carboxyethyl)-phosphine 
TFAM   Mitochondrial transcription factor A 
TFV   Tenofovir 
TMCII4  Darunavir 
TMD   Transmembrane domain 
TPV   Tipranavir 
TTBS   Tween 20-Tris buffered saline 
UCP   Uncoupling protein 
UPR   Unfolded protein response 
UPRmt   Mitochondrial unfolded protein response 
UTR   Untranslated region 
Vif   Viral infectivity factor 
Vpr   Viral protein R 
Vpu   Viral protein U 
xix 
 





Nucleoside reverse transcriptase inhibitors (NRTIs) are the most extensively used antiretroviral 
(ARV) drugs in highly active antiretroviral therapy (HAART). The long term use of HAART is 
associated with changes to metabolic parameters leading to lipodystrophy and metabolic syndrome, as 
well as toxicity to high energy demand organs e.g. liver, kidney, heart, and nervous system. 
Underlying the myriad of NRTI-associated adverse health outcomes is mitochondrial (mt) toxicity. 
Although inhibition of mtDNA synthesis was one of the first identified mechanisms of toxicity, it did 
not provide a holistic explanation for all NRTIs. Furthermore, variations in adaptive stress responses 
were observed following acute and chronic exposure to NRTIs. Insight gained from the molecular 
changes induced by NRTIs will enable effective management and limit adverse health outcomes. 
The human hepatoma (HepG2) cell line was used as an in vitro model to investigate changes to mt 
function, cellular redox status, and antioxidant response following acute [24 hour (h)] and prolonged 
(120 h) exposure to NRTIs – Zidovudine (AZT, 7.1µM); Stavudine (d4T, 4µM); Tenofovir (TFV, 
1.2µM). Long term exposure to AZT and d4T reduced mtDNA levels (120h, AZT: 76.1%; 
d4T:36.1%, p<0.05) and mt function was compromised as evidenced by reduced ATP levels (AZT: 
38%; d4T: 56.4%) and increased mt membrane depolarisation (p<0.02). Tenofovir compromised mt 
function at 120 h independently of depleting mtDNA levels. Oxidative stress parameters were 
significantly elevated by AZT and TFV at 24h; and all NRTIs at 120 h (p<0.05). Endogenous 
antioxidant response was highest in TFV in both time periods (120h; p<0.05). 
Once NRTI induced oxidative stress in HepG2 cells was established, protein homeostatic response to 
oxidative stress was investigated. Lon protease expression and related endoplasmic reticulum (ER) 
stress was evaluated. The data showed that ATP-dependent protein homeostasis responses Lon, heat 
shock protein 60 (HSP60) and ER stress were significantly increased at 24 h (>2 fold); but 
significantly decreased at 120 h for all NRTIs (p<0.005). 
The compromised ATP-dependent stress response then led to the assessment of an ATP- dependent 
drug transporter responsible for efflux of xenobiotics in hepatocytes. The transporter, ATP-binding 
cassette C4 (ABCC4), is regulated by microRNA (miR-) 124a. Regulation of ABCC4 by miR-124a 
has implications for bio-accumulation and resultant toxicity. An inverse relationship between miR-
124a and ABCC4 mRNA levels in all treatments at both time periods was observed. All NRTIs 
elevated miR-124a levels at 24 h (p=0.0009) and this observation was consistent in d4T and TFV 
treated HepG2 cells at 120 h (p<0.0001). This was accompanied with a concomitant decline in 
ABCC4 mRNA levels (p<0.0001) relative to the control. Prolonged exposure to AZT caused a 
decrease in miR-124a and elevated ABCC4 mRNA levels. Protein expression of multi-drug resistance 
protein 4 (MRP4), coded for by ABCC4, did not correlate to mRNA expression. At 120 h, all NRTIs 
xxi 
 
caused significant depletion of MRP4 (possibly due to oxidative cell membrane damage or ATP 
depletion). 
In conclusion, all three NRTIs compromised mt function and induced oxidative damage in HepG2 
cells, with greater toxicity over 120 h. Reduced ATP levels compromised the ATP-dependent stress 
response proteins and xenobiotic detoxification. Tenofovir could be considered a safer alternative as it 





Human immuno-deficiency virus (HIV), the causative agent of Acquired Immuno-Deficiency 
Syndrome (AIDS), is a retrovirus that progressively impairs the immune system. The immuno-
suppression observed in AIDS increases the risk of often fatal opportunistic infections. The first 
clinical observation of AIDS was made in 1981 in a group of homosexual intravenous drug users 
(CDC, 1982), and the AIDS epidemic officially began in June 1982. As of 2013, it is estimated that 
there are 35 million people infected with HIV globally (UNAIDS, 2013). In South Africa, 
approximately 12% of the population are HIV positive (Simbayi et al., 2014). Comparatively, 
HIV/AIDS is the 5th leading cause of death, and the leading communicable disease related cause of 
death in the world (WHO, 2014). The socio-economic impact of HIV/AIDS has pushed this disease to 
the forefront of clinical and molecular research.  
The advent of anti-HIV treatment was one of the most significant advancements in modern medicine. 
According to UNAIDS, there were an estimated 11.7 million people on antiretroviral (ARV) therapy 
in 2013 (UNAIDS, 2013). Prior to the 1990’s, the only treatment available was the management of 
AIDS related opportunistic infections. In 1991 the first ARV drug against HIV, Zidovudine (AZT), 
was approved by the Food and Drug Administration (FDA). Today, there are twenty four ARV drugs 
that are FDA-approved for HIV treatment. Antiretroviral therapy works on the principle of inhibiting 
the viral life cycle. This prevents the replication of mature, infectious virus, thus reducing viral load.  
Antiretroviral drugs are categorized according to the phase of the viral life cycle that they target. 
There are six major classes of ARV drugs: nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
integrase inhibitors and fusion/entry inhibitors. The most effective form of therapy is a combination of 
various classes of drugs. First line therapy usually includes two NRTIs and one PI or NNRTI. Triple 
drug therapy, known as highly active antiretroviral therapy (HAART), is a potent and effective 
therapy in suppressing viral load (Arts and Hazuda, 2012).  
The incidence of opportunistic infections due to immuno-suppression has declined in HIV positive 
patients on HAART, with noticeably decreased mortality. The chronic nature of anti-HIV treatment, 
however, has seen the emergence of long term side effects. Adverse side effects lead to lack of 
adherence in patients, increasing the risk of viral drug resistance (Duran et al., 2001). Toxicity 
depends on a variety of factors including exposure time, drug concentration, pharmacokinetics, and 
tissue specificity. Although individual drugs have varying toxicities, class specific health outcomes 
have been observed over time (Montessori et al., 2004). Protease inhibitors, for example, have been 
associated with insulin resistance leading to type 2 diabetes mellitus; and altered fat metabolism 
favouring dyslipidaemia and lipodystrophy (Carr et al., 1998). Rashes and lipid disorders are common 
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outcomes of NNRTI use (Reust, 2011). Nucleoside reverse transcriptase inhibitors appear to have 
toxic profiles reminiscent of mitochondrial (mt) diseases (Kohler and Lewis, 2007, Montaner et al., 
2003). 
Nucleoside reverse transcriptase inhibitors are the most extensively used class of anti-HIV drugs. 
These drugs are the cornerstone of HAART and are also used in non-infected individuals as pre-
exposure prophylaxis (Celum and Baeten, 2012, Service, 2014). The cost effectiveness of NRTIs 
Lamivudine (3TC) and Stavudine (d4T) make these drugs the basis of first line therapy in developing 
countries (Subbaraman et al., 2007). This standardized approach to ARV therapy doesn’t take into 
account drug interactions in individual patients. Under these circumstances, drug toxicity and adverse 
side effects are common occurrences. The most pressing side effects related to NRTI use are changes 
to fat metabolism, favouring lipodystrophy and metabolic syndrome, hepatic steatosis, peripheral 
neuropathy, hyperlactatemia, lactic acidosis, pancreatitis, cardiomyopathy and peripheral myopathy 
(Carr and Cooper, 2000, Moyle, 2000). 
Underlying the myriad of adverse health outcomes associated with long term NRTI use is 
compromised mt function (Brinkman et al., 1998). Thymidine analogues, including AZT and d4T, 
cause severe depletion of mtDNA by inhibition of the enzyme DNA polymerase (pol) ɣ (Kakuda, 
2000). Depletion of mtDNA causes compromised biosynthesis of components of the electron 
transport chain (ETC). Consequently, cellular energy status, redox balance and mt regulated 
metabolism is disrupted. 
Stavudine is considered a mt toxicant, but is still used in developing countries due to its cost 
effectiveness. A strong link between lipodystrophy, depleted mtDNA in adipose tissue, and d4T use 
has been established (van der Valk et al., 2004, McComsey et al., 2005, Shikuma et al., 2001). 
Chronic use of d4T-containing regimens has also been associated with pancreatitis, lactic acidosis and 
hepatic steatosis (Miller et al., 2000, Makinson et al., 2008, Bolhaar and Karstaedt, 2007). When 
toxicity presents itself, d4T is usually substituted with Tenofovir (TFV) or AZT (Castelnuovo et al., 
2008, Gallant et al., 2004, Domingo et al., 2004). Substitution of d4T with TFV improves 
dyslipidaemia, subcutaneous fat and mt toxicity profiles (Domingo et al., 2004, Ribera et al., 2008). 
Although TFV exhibits lower mt toxicity in adipose tissue, mt toxicity has been identified as a cause 
of renal failure with TFV use (Kohler et al., 2009). Zidovudine also exhibits mt toxicity leading to 
myopathy and cardiomyopathy (Dalakas et al., 1990, Tanuma et al., 2003). Although d4T, AZT and 
TFV exhibit varying toxicity profiles in different tissues, target tissues are all high energy demand and 
rich in mitochondria. Compromised mt function is not always correlated to mtDNA levels, hence new 
avenues of mt toxicity mechanisms need to be investigated. 
The liver is the metabolic hub of the body and is responsible for chemical modification of xenobiotics, 
aiding in excretion. Due to the high level of drug metabolising enzymes, hepatocytes bear the brunt of 
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oxidative insult and xenobiotic accumulation (Park et al., 1995). Cytoprotective stress response are 
imperative to maintaining homeostasis and preventing drug induced liver damage. The antioxidant 
defence and mt biogenesis regulators are the major components of cytoprotection during mt toxicity. 
The master regulator of the antioxidant response, nuclear-erythroid 2-related factor 2 (Nrf2), 
translationally regulates a battery of antioxidant defence genes (Nguyen et al., 2009).  This 
transcription factor has already been recognised for its protective role in drug induced cytotoxicity 
(Copple et al., 2008). Furthermore, Nrf2 induces the expression of mt biogenesis genes, overlapping 
its function with peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α) 
(Piantadosi et al., 2008). An increase in mt biogenesis markers is a compensatory mechanism in mt 
disease and toxicity. Both PGC-1α and Nrf2 are central to maintaining mt function and antioxidant 
response in mt rich tissue, including the liver (Itoh et al., 1997, Finck and Kelly, 2006). 
The clearance of proteins subject to oxidative damage is also an important molecular mechanism in 
NRTI toxicity. Inability to clear oxidatively modified proteins, and particularly mt proteins, is 
characteristic of biological aging (Farout and Friguet, 2006, Bulteau et al., 2006). Chronic use of 
NRTIs has been related to accelerated aging and age-associated disorders (Smith et al., 2012). 
Compromised proteolytic clearance of damaged proteins during NRTI-induced oxidative stress is a 
likely contributor to the observed conditions. The mt matrix protein Lon protease (Lon) is the main 
protease responsible for maintaining mt protein homeostasis (Gur and Sauer, 2008). Lon works in 
conjunction with the endoplasmic reticulum (ER) stress response to mediate proteolytic clearance of 
misfolded proteins and protein occlusions. To date only one study has evaluated Lon mRNA 
expression in relation to HAART (Pinti et al., 2010). The study showed up-regulation of Lon in 
adipose tissue of patients on HAART presenting with lipodystrophy. This implicates Lon as a stress 
response to NRTI toxicity. 
Alternative detoxification mechanisms may also be provided by cellular drug transporters which 
function to reduce the intracellular concentration of NRTIs, reducing bioaccumulation. In this regard, 
the ATP-binding cassette (ABC) family of transporters facilitates cellular export of NRTIs in liver 
cells (Keppler, 2011). These transporters are known to be induced by Nrf2, implicating these 
membrane proteins in stress response (Aleksunes et al., 2008). Furthermore, TFV and AZT have been 
identified as substrates for ABCC4, a member of the ABC family. Differential regulation of ABCC4 in 
hepatocytes will influence the intracellular concentration of NRTIs, having implications for toxicity. 
Epigenetic regulation of drug transporters is a relatively new field of research linking microRNA 
(miRNA) to drug resistance/toxicity (He et al., 2015). MicroRNAs are small non-coding RNA that 
cause post-translational repression. These regulators are highly relevant to ABC transporters, with 
various miRNAs targeting multiple ABC transporters (Haenisch et al., 2014). The regulation of ABC 
transporters by miRNA has not been investigated with NRTI toxicity. 
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We hypothesized that NRTIs (AZT, d4T and TFV) induced biochemical stress responses following 
acute (24 h) and prolonged (120 h) exposure at maximum plasma level concentrations in human 
hepatoma (HepG2) cells. 
In order to test the hypothesis we measured cytoprotective effects involved in mt function, oxidative 
stress, protein homeostasis and epigenetic regulation of cellular detoxification in HepG2 (liver) cells. 
The specific research objectives were assessed as follows: 
- mitochondrial and oxidative stress response following acute and prolonged exposure to 
NRTIs 
- ATP-dependent protein maintenance networks in response to acute and prolonged NRTI-
induced oxidative stress 
- differential regulation of ATP-dependent efflux drug transporter (ABCC4) by microRNA-







2.1. Human Immuno-Deficiency Virus 
2.1.1. HIV morphology 
The structural biology and biochemistry of HIV has been a focus point for therapeutic intervention. 
The virus belongs to the lentivirus genus, a subgroup of the family Retroviridae. Unlike most viruses, 
HIV is spherical in structure, with a diameter of 100-120nm (Sierra et al., 2005). There are two 
identified HIV strains: - HIV-1 and HIV-2. HIV-1 is more virulent and is the more commonly 
observed strain globally. HIV-2 has a much lower virulence/infectivity and is isolated to areas of 
West Africa.  
The HIV genome consists of two identical 9.2kb single RNA strands (Sierra et al., 2005). The genome 
contains three open reading frames (ORF) for structural proteins. Group specific antigen (Gag) 
encodes for all structural proteins [matrix (MA), capsid (CA) and nucleocapsid (NC)]. The 
polymerase (pol) ORF encodes for all viral enzymatic components [protease (PR), reverse 
transcriptase (RT), integrase (IN), ribonuclease]. Finally, the envelope (Env) ORF encodes  viral 
envelope proteins [glycoprotein (gp)120, gp41] (Wilk and Fuller, 1999). The HIV genome encodes 
for a further six accessory genes involved in the regulation of viral replication: Trans-activator of 
transcription (Tat), regulator of expression of virion proteins (Rev), negative factor (Nef), viral 




Figure 2.1: Diagram of HIV mature virion. The lipid bi-layer is derived from the host cell. The 
structural proteins forming the core are matrix protein (p17), capsid protein (p24), and 
nucleocapsid (p7). The capsid contains the two strands of viral RNA and viral enzymes 
including reverse transcriptase (Karlsson Hedestam et al., 2008) 
The virion is enveloped in a bi-layer of phospholipids that are of cellular origin. On the viral envelope 
are protein protrusions which facilitate binding to the host cell. The protrusions are anchored by the 
transmembrane protein, gp41. Viral protein gp120 projects out of the viral envelope to facilitate 
attachment to the host cell and subsequent fusion. Enclosed in the viral envelope is the viral MA, 
consisting of viral protein p17, which maintains the structural integrity of the virion. At the viral core 
is the CA. The CA is conical and is constituted of viral protein p24. Within the CA, two strands of 
viral RNA are tightly bound to p7, the viral NC protein. Also contained in the NC are the enzymes 
required for viral replication: RT, IN, PR (Ganser-Pornillos et al., 2008, Sierra et al., 2005, Turner and 
Summers, 1999). 
2.1.2. Viral replication 
HIV primarily targets immune cells such as CD4+ helper T cells, macrophages, dendritic cells and 
microglial cells. The CD4 receptor on the immune cell is a docking site for gp120. Once bound to the 
host cell, gp120 undergoes further interaction with chemokine co-receptors, particularly CXCR4 and 
CCR5 (Clapham and Weiss, 1997, Doranz et al., 1996, Feng et al., 1996). These receptors are 
determinants of the tropism of HIV. This interaction causes a conformational change that exposes the 
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hydrophobic domain of gp41, allowing fusion with the host cell. An uncoating event takes place, 
releasing the CA, containing viral genomic material and enzymes, into the cytosol of the host cell 
(Figure 2.2). 
 
Figure 2.2: Viral replication of HIV-1 (Ganser-Pornillos et al., 2008) 
Upon entry into the cytosol, viral RNA is reverse transcribed by RT, forming the viral pre-integration 
complex. This process is thought to be regulated by accessory protein Vif (Turner and Summers, 
1999). Nuclear localization of the viral DNA is an active process regulated by MA, IN, RT and Vpr 
(Bukrinsky et al., 1993, von Schwedler et al., 1994). Integration of viral and host DNA takes place in 
the nucleus. The viral enzyme IN mediates three sequential processes for integration into the human 
chromosome. Firstly the assembly of viral DNA, secondly endonucleolytic processing of the 3’ end of 
viral DNA, and finally the joining of the strand to cellular DNA (Arts and Hazuda, 2012). This 
process results in the production of unspliced and spliced mRNA transcripts. The short spliced RNA 
species encode for Tat, Rev and Nef. Regulatory protein Tat is vital for transcriptional activation. The 
full length or singly spliced viral RNA contains the introns encoding for Gag and Pol. These need to 
be exported to the cytosol for synthesis to occur. The export of the viral RNA is regulated by Rev, 
which binds to the Rev-response element. The formation of this complex recruits protein exportin 1, 
allowing transport of the viral DNA through a nuclear pore (Ohno et al., 1998). 
The viral spike gp120 is derived from gp160, a genomic derivative of Env, and is synthesized in the 
endoplasmic reticulum (ER). From the ER the polyprotein gp120 is transported through the Golgi 
apparatus and cleaved by furin to gp120 and gp41. These processed proteins, together with Gag, Gag-
Pol, and the viral RNA aggregate at the plasma membrane, enabling the assembly phase. The virion 
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then begins to bud off the host cell (Figure 2.2). The Gag polyproteins will still need to be further 
cleaved by PR. Once all the structural components have assembled a mature, infectious virion is 
formed. Mature virus is capable of entering CD4+ cells and utilizing the cellular machinery for viral 
replication. 
Inevitably, the CD4+ T cell pool is significantly depleted as viral replication is sustained. The majority 
of CD4+ cell loss is due to apoptotic cell death (Gougeon et al., 1996). The progressive decline in 
immune cells compromises both innate and adaptive immunity, eventually increasing susceptibility to 
opportunistic infections. Commonly observed health outcomes include Kaposi sarcoma, lymphoma, 
and infection with tuberculosis, bacterial pneumonia, Cryptococcus, herpes simplex, cytomegalovirus, 
(Kaplan et al., 2009). In order to maintain CD4+ T cells at a sustainable level to confer protection, 
viral replication is a key target in reducing the infectivity of HIV. 
 
2.2. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 
2.2.1. Nuclease Reverse Transcriptase Inhibitors 
Nuclease reverse transcriptase inhibitors (NRTIs) were the first class of drugs approved by the Food 
and Drug Administration (FDA) for HIV treatment. These drugs form the backbone of highly active 
antiretroviral therapy (HAART). This class of drugs functions to inhibit viral RT in a competitive 
fashion. All NRTIs are designed as analogues of native nucleosides/nucleotides. 
Table 2.1: List of FDA approved NRTIs used in HAART (WHO, 2010) 
Drug Name Trade Name Functional Analogue 
Abacavir (ABC) Ziagen Guanosine 
Emtricitabine (EVG) Emtriva Cytidine 
Didanosine (ddI) Videx Guanosine 
Lamivudine (3TC) Epivir Cytidine 
Stavudine (d4T) Zerit Thymidine 
Zalcitabine (ddC) Hivid Pyrimidine 
Entecavir (ETV) Baraclude Guanosine 
Zidovudine (AZT) Retrovir Thymidine 
Tenofovir (TFV) Vired Adenosine 
 
Reverse transcriptase is responsible for the conversion of single stranded viral RNA to double 
stranded DNA upon entry of the virus into the host cell. Viral transcription utilizes cellular native 
nucleotides for strand synthesis. Antiretroviral (ARV) drugs belonging to the class NRTI lack the 3’-
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OH group at the sugar moiety of the base. Integration of the NRTI during transcription results in chain 
termination, thus preventing full length viral DNA strand synthesis (Arts and Hazuda, 2012). All 
NRTIs are administered as pro-drugs. They require addition of a triphosphate group by cellular 
kinases to become active. Tenofovir (TFV), however, requires the addition of a diphosphate group in 
order to be activated. 
2.2.2. Non-nucleoside Reverse Transcriptase Inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNTRIs) are a chemically diverse class of ARV 
drugs that also target viral RT. They are primarily metabolized by the enzymes cytochrome P (CYP) 
3A4 and CYP1B1, belonging to the CYP450 family. These are used alongside NRTIs to reduce the 
chances of viral resistance, and may have synergistic anti-viral activity (Basavapathruni et al., 2004). 
Unlike NRTIs, the mechanism of inhibition is non-competitive. Furthermore this class of drugs is 
specific to HIV-1, and is unable to inhibit the replication of other lentivirus, including HIV-2 (De 
Clercq, 1998). The mechanism of action in NNRTIs is not unlike that of NRTI therapy, in that both 
manipulate the viral enzyme, RT. However, the mode of action differs as NNRTIs do not bind to the 
active substrate docking site of the enzyme. These drugs bind covalently to a site proximal to the 
active site (Figure 2.3). The NNRTI induces the formation of a hydrophobic pocket, changing the 
structural configuration of RT. This prevents the substrate (native nucleotides) from docking at the 
active site of RT, resulting in the termination of viral DNA strand synthesis (de Béthune, 2010, De 
Clercq, 1998). 
 
Figure 2.3: Ribbon representation of reverse transcriptase (RT) complex with NNRTI. Red 
represents viral subunit p66 and blue indicates subunit p51. Image adapted from Sluis-Cremer 
and Tachedjian, 2008 (Sluis-Cremer and Tachedjian, 2008) 
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As of 2013 the following FDA approved NNRTIs are available globally: Etravine (Intelence), 
Delavirdine (Rescriptor), Efavirenz (Sustiva), and Nevirapine (Viramune). Rilpivirine (Edurant) is in 
phase 3 of clinical trials. 
2.2.3. Protease Inhibitors 
Protease inhibitors (PIs) are considered the most potent anti-HIV agents. However, they also display 
many side effects. These drugs target the late phase of the viral replication cycle, by inhibiting viral 
PR. Protease functions to cleave Gag and Gag-Pol polypeptide precursors during viral maturation 
(Park and Morrow, 1993). Inhibition of this enzyme prevents the formation of mature, infective virus. 
There are currently 10 PIs approved by the FDA, as listed in Table 2.2. 
Table 2.2: List of FDA approved Protease Inhibitors for HIV treatment (WHO, 2010) 
Drug Name Abbreviation Trade Name 
Amprenavir APV Agenerase 
Atazanavir ATZ Reyataz 
Darunavir TMCII4 Prezista 
Fasamprenavir  - Lexiva 
Indinavir IDV Crixivan 
Lopinavir LPV Aluvia 
Rotinavir RTV Norvir 
Lopinavir+Rotinavir  - Kaletra 
Nelfinavir NFV Viracept 
Saquinavir SQV Fortovase/Invirase 
Tipranavir TPV Aptivus 
 
2.2.4. Entry inhibitors 
Entry inhibitors consist of two distinct classes – fusion inhibitors and CCR5 antagonists. 
2.2.4.1. CCR5 antagonists 
This branch of drugs functions as allosteric inhibitors of viral entry. CCR5 is one of the main co-
receptors utilized by gp120 to initiate the fusion step during viral replication. Antagonists of CCR5 
are generally small molecules that occupy the hydrophobic pockets between the helices of the CCR5 
receptor. The presence of these small molecules results in a conformational change in the CCR5 
receptor, making it unrecognisable to the virus. The receptor cannot be used to gain entry into the cell. 
There are currently 3 CCR5 antagonists on the market: Aplaviroc, Vicriviroc and Maraviroc (Dorr et 
al., 2005).  
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2.2.4.2. Fusion inhibitors 
The fusion phase of the viral life cycle requires the interaction of two domains of the gp41 
transmembrane protein – Heptade repeat 1 and 2. These two motifs bind to each other, creating a 
hairpin structure, pulling the cell membrane toward the viral membrane. Fusion inhibitors mimic one 
of these domains and interrupt the intra-molecular interaction (Lalezari et al., 2003). These drugs also 
sensitize the virus to antibodies specific against gp41, as they prolong the exposure time during 
fusion.  
2.2.5. Integrase inhibitors 
Integrase processes the 3’ end of viral DNA and facilitates strand joining of viral DNA to host DNA. 
Integrase inhibitors are the newest discovery in targeted ARV therapy (Espeseth et al., 2000, Hazuda 
et al., 2004).  Raltegravir, the first integrase inhibitor, was approved in 2007. Other integrase 
inhibitors are still in the clinical trial phase (Sato et al., 2006, Shimura and Kodama, 2009). These 
drugs inhibit viral DNA strand transfer by binding to the complex between viral RNA and IN. 
Integrase inhibitors possess a metal-binding pharmacophore, enabling the drug to interact with 
magnesium ion co-factors which are essential for IN function. 
 
2.3. ANTIRETROVIRAL DRUGS AND ADVERSE HEALTH OUTCOMES 
2.3.1. Clinical outcomes 
2.3.1.1. Lipodystrophy 
Lipodystrophy is a condition characterized by loss of subcutaneous adipose in the face, limbs and 
buttocks, with abdominal and visceral accumulation of fat. Dorso-cervical fat accumulation referred 
to as “buffalo hump” or “fat pad” is also a symptom affiliated with lipodystrophy. Lipodystrophy is 
observed in a subset of patients on HAART. Patients with lipodystrophy need not present with all the 
above mentioned clinical outcomes. Both NRTIs and PIs are associated with the development of 
lipodystrophy (Carr et al., 2000, Villarroya et al., 2010, Tsiodras et al., 2000). HIV infection also 
plays a role in the pathogenesis of the disorder (Riddler et al., 2003). 
The molecular mechanism leading to the physiological outcomes of lipodystrophy is attributed to the 
active lipolysis of subcutaneous fat in peripheral regions. Stavudine (d4T)-containing therapy has a 
strong correlation with the onset of lipodystrophy. A proposed mechanism in this instance is adipose 
specific mitochondrial (mt) toxicity (Shikuma et al., 2001, McComsey et al., 2005, van der Valk et al., 
2004). Excessive lipolysis leads to elevated free fatty acids in circulation and the deposition of fat in 
visceral regions such as the stomach, back and behind the neck (Villarroya et al., 2005). The elevation 
of circulating free fatty acids, particularly triglycerides, has metabolic repercussions. Insulin 
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resistance, elevated total cholesterol, heightened low density lipoprotein cholesterol, and reduced high 
density lipoprotein cholesterol are observed as consequences of lipodystrophy. Such metabolic 
outcomes are reminiscent of metabolic syndrome. These factors increase the risk of developing type 2 
diabetes and cardiovascular disease (Estrada et al., 2006, Villarroya et al., 2010). 
2.3.1.2. Hepatic steatosis 
Hepatic steatosis, or fatty liver, is a condition whereby the abnormal retention of lipids causes the 
formation of triglyceride-containing vacuoles in the liver. Hepatic steatosis is a consequence of 
disrupted fat metabolism (Reddy and Rao, 2006). The environment created in the event of steatosis 
promotes inflammation, increasing the risk of hepatitis. Nuclease reverse transcriptase inhibitors: d4T, 
Zidovudine (AZT) and Didanosine (ddI), have been associated with this condition. The pathological 
mechanism by which these drugs cause hepatic steatosis is via mt toxicity and consequently disrupted 
lipid metabolism (McGovern et al., 2006, Sulkowski et al., 2005). A study conducted by Sulkowski 
et. al in 2005 in a cohort of 137 male HIV patients found 40% of HIV and hepatitis C co-infected men 
on extensive ARV therapy presented with hepatic steatosis. Stavudine was recognised as a modifiable 
risk factor in this study. Another study by Sutinen et. al (2002) showed hepatic fat accumulation in 
patients with HAART-associated lipodystrophy may play a causative role in insulin resistance 
(Sutinen et al., 2002). 
2.3.1.3. Hyperlactataemia 
Lactic acidosis is a rare but potentially fatal outcome of NRTI use. Chronic elevated levels of lactic 
acid is not unusual for HIV infected individuals on HAART (John et al., 2001). Lactic acidosis only 
presents itself following long term use of NRTIs. The proposed mechanism by which NRTIs increase 
lactate levels is the inhibition of the enzyme responsible for mtDNA replication, DNA polymerase 
(pol) ɣ (Figure 2.4). Lactate is a product of anaerobic glycolysis. In the event of mt dysfunction, 
compromised aerobic respiration shunts pyruvate into lactate production. Long term use of NRTIs, 
especially strong inhibitors of DNA pol ɣ, leads to the progressive depletion of mtDNA. The result is 
a reduction in the proteins coded for by mtDNA and subsequent disruption of mt function. During 
normal glycolysis glucose is converted to pyruvate in the cytoplasm. Pyruvate then enters the 
mitochondria, where it is converted to Acetyl coenzyme A, which in turn enters the tricarboxylic acid 
(TCA) cycle. The product of the TCA cycle is NADH, which is utilized in ATP production during 
oxidative phosphorylation (OXPHOS). When mt function is disrupted, the utilization of pyruvate by 
mitochondria is compromised. This allows pyruvate to accumulate in the cytoplasm, eventually being 





Figure 2.4: Mechanism by which NRTI-associated mitochondrial toxicity causes lactic acidosis 
(Figure by author) 
Lactic acidosis is usually accompanied by hepatic steatosis, further implying mt dysfunction as a 
causative mechanism. Females on HAART are at higher risk of developing lactic acidosis and 
hyperlactataemia as compared to males (Bolhaar and Karstaedt, 2007). Furthermore, uninfected 
infants exposed in utero to ARV drugs also display elevated levels of lactate (Alimenti et al., 2003). 
Previous work done by Montaner et. al in 2003 showed reduced mtDNA preceded the elevation of 
venous lactate levels in patients on HAART (Montaner et al., 2003). 
2.3.2. Biochemical outcomes 
2.3.2.1. Mitochondrial Toxicity 
The mitochondrion is the metabolic hub of the cell and integrates vital multi-cellular pathways 
(Figure 2.5). The varied side effects of NRTIs are all linked to disrupted mt function. Mitochondrial 
toxicity provides a single explanation for a myriad of adverse clinical outcomes as shown in Figure 
2.6. Mitochondria-rich tissue with high energy demand (cardiac, hepatic, neuronal, renal) display 
increased susceptibility to NRTI toxicity (Apostolova et al., 2011).  Mitochondrial-driven 
physiological processes, particularly lipid metabolism, are altered with NRTI use (Carr et al., 2000). 
Mitochondrial DNA replication and transcription, mt biogenesis, protein synthesis, mt membrane 
integrity, mt matrix metabolism and ATP production have all been identified as possible targets for 




Figure 2.5: Schematic representation of physiological functions of mitochondria (adapted from 
Apostolova, Blas-García et al. 2011). Mitochondrial toxicants, such as NRTIs, can have far 




Figure 2.6: Schematic representation of clinical outcomes in NRTI-associated mt toxicity. 
Individual ARVs display tissue specific toxicity. AZT: Zidovudine; ddC: Zalcitabine; ddI: 
Didanosine; d4T: Stavudine; TFV: Tenofovir (Figure by author) 
 
2.3.2.2. DNA polymerase gamma hypothesis 
The identification of NRTI associated mt toxicity led to the interrogation of this pathological 
mechanism. One of the earliest theories relating NRTI exposure to mt dysfunction was the “DNA pol 
15 
 
ɣ hypothesis.” Aside from being a substrate for viral RT, NRTIs also serve as substrates for 
endogenous polymerases. Of the five human polymerase enzymes, DNA pol ɣ is the sole enzyme 
responsible for mtDNA replication and has a high affinity for specific (thymidine analogues) NRTIs 
(Kakuda, 2000). Incorporation of NRTIs during mtDNA replication results in chain synthesis 
termination. 
Mitochondria have their own DNA distinct from nuclear DNA. Mitochondrial DNA is circular and 
codes for 13 proteins. Proteins coded for by mtDNA are essential subunits in the electron transport 
chain (ETC) and are required for efficient OXPHOS. Chronic exposure to NRTIs results in depleted 
mtDNA levels (Lewis and Dalakas, 1995).Theoretically, depleted mtDNA levels compromise the 
functionality of the ETC and OXPHOS, resulting in deficient ATP production, mt membrane 
depolarisation and an elevation in the production of reactive oxygen species (ROS). 
Each NRTI has an individual toxicity profile; with dideoxynucleotide analogues [d4T; Zalcitabine 
(ddC); ddI] and AZT having the highest potential to inhibit mtDNA synthesis (Brinkman et al., 1998). 
Weak inhibitors of DNA pol ɣ such as Lamivudine (3TC) and Tenofovir (TFV) were regarded as 
safer options in combination therapy (Curran and Ribera, 2011, Rosso et al., 2008). A study 
conducted by Birkus et. al. in 2002 evaluated the mt toxicity of various NRTIs in human hepatoma 
(HepG2) cells. The study concluded that the ranking of mt toxicity of the NRTIs studied from most 
severe to least severe were as follows: ddC > ddI > d4T > AZT > TFV = 3TC = ABC (Birkus et al., 
2002). Another study by the same authors also assessed the cytotoxicity of NRTIs in HepG2 cells, 
human skeletal muscle and myeloid cells; the study ranked toxicity as follows: ddC > AZT > d4T > 
TFV > 3TC (Cihlar et al., 2002). 
Inconsistencies have been observed in studies both in vivo and in vitro correlating mtDNA levels with 
mt toxicity and associated clinical outcomes (Apostolova et al., 2011).  Tenofovir is a relatively new 
introduction to HAART and is considered a safer alternative due to its weak inhibition of DNA pol ɣ. 
However, TFV has been shown to induce mt structural changes and mt dysfunction while maintaining 
mtDNA levels in rat kidneys, contributing to nephropathy (Kohler et al., 2009). It is clear that mt 
toxicity exerted by NRTIs goes beyond DNA pol ɣ inhibition. Alternative mechanisms to NRTI 
induced toxicity that have been proposed include depletion of ATP, mt biogenesis, depleted native 
nucleotide pools, transcription of mtDNA, mt membrane integrity and protein synthesis (Setzer et al., 
2008, Cohen, 2010). 
2.3.2.3. Mitochondrial biogenesis 
Respiratory capacity is dependent on the number of functional mitochondria. Mitochondrial 
biogenesis refers to the replication of mitochondria by division of existing mitochondria. The 
biogenesis of mitochondria is regulated transcriptionally by both the nuclear and mt genome. The 
main regulator of mt biogenesis is a nuclear encoded transcriptional co-activator: peroxisome 
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proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α) (Wu et al., 1999). The activity 
of PGC-1α is induced as a metabolic adaptation to stress conditions or changes in energy status 
(Cantó and Auwerx, 2009). The role of PGC-1α in mt biogenesis is via its interaction with nuclear 
respiratory factor 1 and 2 (NRF1; NRF2); as well as up-regulating genes coding for ETC subunits – 
cytochrome c oxidase I and II and ATP synthase (Wu et al., 1999). 
Together, PGC-1α and NRF1 coordinate the transcription of nuclear encoded genes required for mt 
biogenesis, most importantly activating mt transcription factor A (TFAM) (Gleyzer et al., 2005). This 
transcription factor is a high mobility group and DNA-binding protein. Upon induction by NRF1, 
TFAM translocates to the mitochondria where it binds to mtDNA, allowing transcription of the 
mitochondrial genome by DNA pol ɣ (Ngo et al., 2011). Furthermore, TFAM plays a role in the 
processing and packaging of mtDNA (Kaufman et al., 2007). 
Mitochondrial biogenesis markers (PGC-1α; NRF1; TFAM) are known to be increased in the event of 
mt dysfunction and oxidative stress (Lee and Wei, 2005). This is likely to be a compensatory 
mechanism during mt dysfunction. Furthermore, PGC-1α also induces the expression of uncoupling 
protein 2 (UCP2) and superoxide dismutase (SOD) in defence against increased oxidative stress 
(Valle et al., 2005); thus PGC-1α acts as a stress response protein. 
Studies on these parameters related to NRTI use are conflicting. Analysis of adipose tissue from HIV 
positive patients following six weeks of AZT/3TC/d4T triple therapy in an Australian cohort showed 
elevated expression of NRF1, TFAM and PGC-1α (Mallon et al., 2005). A similar study in the United 
Kingdom quantified gene expression in adipose tissue after 18-24 months of NRTI therapy. The 
results of the study showed TFV and AZT elevated PGC-1α expression, but reduced NRF1 (Boothby 
et al., 2009). A South African cohort displayed a reduction in NRF1 expression in adipocytes 
following 4 weeks treatment with d4T/EFV dual therapy (Menezes et al., 2013). Stavudine treated 
HepG2 cells, however, showed an increase in nuclear mt biogenesis transcripts (Setzer et al., 2008). 
From the above described literature it is clear that mt biogenesis genes are differentially expressed 
depending on tissue type and exposure time to NRTIs. 
2.3.2.4. Mitochondrial free radical production 
One of the most common outcomes of mt dysfunction is elevated mt free radical production. 
Naturally, the mt toxicity displayed by NRTIs is likely to contribute to an imbalance in cellular redox 
state. Previous studies have shown that a link exists between HAART use and elevated free radical 
production and markers for oxidative damage (Mondal et al., 2004, Ngondi et al., 2006, Masia et al., 
2007).  
 
Reactive oxygen species are a natural by-product of cellular respiration, making mitochondria the 
major endogenous source of ROS. Four electron transporting complexes (I-IV) and ATP synthase 
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facilitate OXPHOS, driving ATP synthesis (Figure 2.7). Products from the tricarboxylic acid (TCA) 
cycle, amino acid metabolism and β-oxidation all feed into ATP synthesis. An electron donor, usually 
NADH or FADH2, is transferred through consecutive complexes via a series of redox reactions. 
Electron transfer is coupled with the transfer of protons (H+) across the mt membrane, creating an 
electro-chemical gradient. The gradient across the inner mt membrane shunts ADP through ATP 
synthase, producing ATP. The final electron acceptor is molecular oxygen (O2). Oxygen is then 
reduced to H2O. 
 
 
Figure 2.7: The electron transport chain is the site of oxidative phosphorylation that drives ATP 
synthesis. Complex I and III have been identified as sites of superoxide production due to 
electron leakage (Senft and Ronai, 2015) 
Under normal physiological conditions, less than 1% of O2 generated during ATP synthesis is 
converted to superoxide (O2•-), a potent free radical (Raha and Robinson, 2000). Although an efficient 
means of energy production, the ETC is termed as “leaky” due to the escape of electrons during 
OXPHOS. Complex I and complex III have been identified as the main sites of electron leakage (Du 
et al., 1998, Beyer, 1992).  
 
Basal levels of ROS have physiological relevance in cell signalling and immune response (Griendling 
et al., 2000, Thannickal and Fanburg, 2000). Insult to mitochondria, however, disrupts ETC function, 
changing the electro-chemical gradient across the inner mitochondrial membrane. This change 
elevates electron leakage from the ETC, thus increasing O2•- production. In the event that the cell 




2.3.2.5. Oxidative stress 
 
 
Figure 2.8: The most physiologically abundant reactive oxygen species (Sies, 1994) 
Oxidative stress is an imbalance in the pro-oxidant/antioxidant system, in favour of the former, that 
often leads to pathological conditions and disease. Free radicals, including ROS, are molecules with 
free valence electrons. These molecules are extremely reactive as they are capable of “stealing” 
electrons from cellular macromolecules. Oxidation of cellular macromolecules including lipids, 
protein and DNA, results in detrimental changes to structure and function. At basal levels, ROS are 
required for intracellular redox signalling (Thannickal and Fanburg, 2000). An over-production of 
ROS, however, increases the rate of free radical reaction with cellular components. Processes that 
may lead to the excessive production of ROS include ionizing radiation, xenobiotic metabolism, 
enzymatic synthesis of nitric oxide, or oxidative burst in phagocytes (Bohr, 2002). 
  
2.3.2.6. Oxidative DNA damage 
The interaction of ROS with DNA bases results in the formation of adducts or lesions. Various 
adducts have been identified (Figure 2.9), however the most widely studied is the guanine 8-oxo-7,8-
dihydroguanine (8-oxoG) (Fortini et al., 2003). This lesion is highly mutagenic and may contribute to 
carcinogenesis. The presence of the 8-oxoG adduct causes mispairing, leading to adenine to cytosine 




Figure 2.9: Oxidized guanine (black) and adenosine (blue) adducts. Substrates for OGG1 are 
indicated in red (Klungland and Bjelland, 2007) 
Removal of the adduct is achieved in both nuclear DNA and mtDNA by the base excision repair 
enzyme, 8-oxoG DNA glycosylase (OGG1) (Stuart et al., 2004). This glycosylase reduces the 
accumulation of 8-oxoG DNA adducts by binding to DNA and cleaving the glycosidic bond of the 
DNA adduct. The activity of OGG1 in NRTI toxicity is particularly important as the repair activity of 
DNA pol ɣ is compromised.  
 
2.3.2.7. Lipid peroxidation 
Although proteins and DNA appear to be more significant targets of ROS, lipid peroxidation is a late 
stage effect of oxidative stress. Biological constituents that are high in polyunsaturated fatty acids 
(phospholipids, and glycolipids) and cholesterol are prime targets for oxidative degradation. Hydroxyl 
radicals (OH•) and hydroperoxyl radicals (OH2) have a high affinity for the double bonds of the 
methylene bridges in polyunsaturated fatty acids. Initiation of lipid peroxidation occurs when a free 
radical extracts allylic hydrogen to form a carbon centred lipid radical. This “electron stealing” 
mechanism is then propagated once the lipid radical reacts with O2, to form a peroxyl lipid radical. 
The peroxyl radical then “steals” a hydrogen atom from adjacent fatty acids, causing a chain reaction 
of lipid radical formation. This chain reaction is only terminated when two lipid radicals react to form 
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a non-radical product or through interaction with an antioxidant electron donor (Ayala et al., 2014, 
Kaufman et al., 2003). The products of lipid peroxidation are toxic and contribute to a variety of 
pathogenic conditions including asthma, neurodegenerative disorders, renal damage, pre-eclampsia 
and metabolic complications (Pham-Huy et al., 2008). The reactive aldehydes: malondialdehyde 
(MDA) and 4-hydroxynonenal are the most commonly studied products of lipid peroxidation and are 
measured as markers of oxidative stress (Requena et al., 1996). Lipid peroxides are usually detoxified 
by vitamin E or endogenous antioxidant enzymes SOD, catalase (CAT), and glutathione peroxidase 
(GPx).  
2.3.2.8. Oxidative protein damage 
Proteins have unique three-dimensional structures that are vital to their biological functionality. 
Protein side chains and polypeptide backbones of proteins are susceptible to oxidation by ROS, 
causing changes to the native protein structure. Oxidation of protein side chain residues cause partial 
unfolding of quaternary structure, while oxidation of protein backbones result in fragmentation 
(Stadtman and Berlett, 1998). The structural changes induced by ROS eventually lead to loss of 
function and contribute to pathological conditions. 
Protein aggregation occurs when hydrophobic stretches of unfolded proteins are exposed following 
oxidative damage. This allows irregular protein interactions and covalent cross-links between 
proteins. There are two fates of protein aggregates:- enzymatic repair or proteolytic degradation. 
Large clusters of protein aggregates, however, may be difficult to remove proteolytically. The 
accumulation of protein aggregates poses a toxic threat, causing structural changes and hindering 
normal physiological processes (Squier, 2001). The inability to remove oxidized protein aggregates is 
believed to be a contributor to biological aging and age-associated degenerative diseases (Squier, 
2001, Berlett and Stadtman, 1997). 
Considering the array of physiological processes mediated by mitochondria, mt protein quality control 
is imperative to well-being. Several adverse health outcomes caused by long term NRTI use have 
been defined as age-associated disorders (Smith et al., 2012). Accelerated aging due to compromised 
mt protein quality control may be a molecular mechanism of toxicity in chronic NRTI use. 
 
2.4. MITOCHONDRIAL PROTEIN QUALITY SURVEILLANCE 
Protein quality control is an evolutionarily conserved mechanism to cope with stressors that cause 
protein misfolding and aggregation. In order to cope with ROS produced by the ETC, the 
mitochondrion possesses an intricate protein maintenance network. The network consists of protein 
chaperones, ATP-dependent proteases and regulatory molecules (Sauer et al., 2004, Bukau et al., 
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2006). During stress conditions that disrupt protein homeostasis, a cellular stress response is induced 
to re-model protein folding and increase the activity of protein chaperones and proteases.  
The ubiquitin-proteasome is generally responsible for the clearance of misfolded proteins or protein 
aggregates. Disruptions to mt protein homeostasis, however, cannot be reliant on cytosolic proteases 
as the mt double membrane hinders accessibility. Mitochondria possess endogenous proteases to 
process damaged proteins, and the products are shuttled by chaperones into the cytosol (Voos, 2009).  
2.4.1. Lon Protease 
Proteolytic clearance in the mt matrix is largely mediated by Lon protease (Lon), a member of the 
ATPases associated with diverse cellular activities (AAA+ family), encoded by LONP1. It is an ATP-
dependent serine peptidase that is essential in mt protein quality control. Lon protease recognizes 
specific sequences that are usually located at the core of folded proteins (and thus inaccessible) but 
are exposed in unfolded proteins (Gur and Sauer, 2008). This enables Lon to distinguish between 
damaged and functional proteins in the mt matrix. Upon recognition of the target sequence, proteins 
are unfolded if necessary, and transferred through a pore to a degradation chamber (Figure 2.10). The 
AAA+ module, which is common to all AAA+ proteases, is a conserved ATP-binding site consisting 
of approximately 200 amino acids (Lee and Suzuki, 2008). Binding of ATP to the AAA+ module of 
Lon causes a conformational change, enabling Lon to become proteolytically active (Sauer et al., 
2004).  
An important substrate for the proteolytic activity of Lon in the mt matrix is oxidized aconitase (Bota 
and Davies, 2002). Aconitase, an enzyme regulating the TCA cycle, is sensitive to oxidative 
inactivation. Upon inactivation, mt aconitase begins to accumulate and aggregate in the mt matrix. 
The accumulation of oxidized mt aconitase is characteristic of biological aging (Yan et al., 1997). 
Proteolytic clearance of oxidized aconitase aggregates by Lon prevents detrimental effects on mt 




Figure 2.10: Schematic representation of mechanism of AAA+ protease activity. Recognition of 
unfolded/damages proteins by a peptide tag facilitates binding of the substrate to the protease. 
ATP-dependent unfolding enables the substrate to enter the degradation chamber (pink). 
Proteolysis occurs when ATP binds to the AAA+ module. Larger fragments may require 
ATPase activity to exit the chamber (Sauer et al., 2004) 
Lon also plays a role in metabolic homeostasis due to its selective degradation of regulatory 
molecules in mt biogenesis. Post-translational phosphorylation of TFAM reduces the DNA-binding 
capability of TFAM, and marks the transcription factor for degradation by Lon (Lu et al., 2013). RNA 
interference of Lon increases both TFAM and mtDNA levels, validating the role of Lon in mt 
biogenesis (Matsushima et al., 2010). The chaperone activity of Lon is also crucial to the assembly of 
the mt subunits that form the ETC (Rep et al., 1996). 
Due to the importance of Lon in mt protein maintenance, it has become a target for mt diseases and 
age-associated disorders. To date, only one study has related Lon mRNA expression to HAART and 
lipodystrophy (Pinti et al., 2010). The study showed significant elevation of Lon mRNA levels in 
adipose tissue obtained from patients on HAART presenting with lipodystrophy. Although this 
finding is highly relevant to NRTI toxicity, Lon protein levels were not evaluated as there is poor 
correlation between Lon mRNA and protein levels (Gibellini et al., 2014). 
2.4.2. Post translational regulation of Lon – Sirtuin 3 
The disjoint between Lon mRNA and protein levels may be due to the rapid response requirement of 
stress proteins. Hypoxia, disrupted energy production, oxidative stress and ER stress are known to 
induce Lon activity (Hori et al., 2002). Post-translation modifications provide a means to increase 
protein turnover without the time consuming synthesis, processing and exportation of de novo mRNA 
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synthesis. A recently identified regulator of Lon is a homolog of the sirtuin (SIRT) family, SIRT3 
(Gibellini et al., 2014). 
Sirtuins are NAD+ dependent deacetylases that regulate various biological processes including cell 
death, metabolism, genomic stability, aging, and antioxidant response (Finkel et al., 2009). Seven 
homologs of this evolutionarily conserved family of proteins exist in mammals i.e. SIRT1-7. Substrates 
and cellular localization may differ between the various SIRTs. Sirtuin 1 is the most extensively studied, 
and along with SIRT 6 and 7, resides in the nucleus. Sirtuin 2 has been identified as a cytoplasmic SIRT. 
Mitochondrial located SIRTs include SIRT3-5 (Haigis and Guarente, 2006). The mt SIRTs are key 
regulators in cellular metabolism. This has made SIRTs a promising target in diabetes and metabolic 
syndrome (Guarente, 2006, Jiang, 2008). Due to its integral role in the mitochondria, the role of SIRT3 
in mt maintenance will be described. 
Sirtuin 3 is vital to mt function as it regulates mt antioxidant response,  mt biogenesis (Kong et al., 
2010, Brenmoehl and Hoeflich, 2013) and recently reported, mt unfolded protein response (UPRmt) 
(Papa and Germain, 2014). The UPRmt is a homeostatic response to maintain the protein folding 
environment in the mitochondrion, as well as mt architecture. Traditionally, UPRmt is thought to be 
mediated by CCAAT-enhancer-binding homologous protein (CHOP) and oestrogen receptor α. 
Sirtuin 3, however, is rapidly emerging as regulator of UPRmt through the induction of mt antioxidants 
SOD2 and PGC-1α, regulation of mitophagy (Papa and Germain, 2014) and post-translational 
modification of Lon (Gibellini et al., 2014). A recent study by Gibellini et al. (2014) demonstrated 
that not only does SIRT3 regulate acetylation (Lys917) status of Lon, but directly interacts with Lon, 
altering its expression. Acetylation is a well-established form of post-translation modification, with 
one third of mt proteins estimated to be acetylated (Zhao et al., 2010). Although the exact role of 
lysine acetylation has not been uncovered, it is suggested that Lon in its acetylated form is more 
stable. 
2.4.3. Lon protease and endoplasmic reticulum stress 
The ER is the hub of protein processing, folding and packaging and is essential to maintaining protein 
homeostasis. The mitochondrion and ER possess co-regulatory mechanisms during stress response. 
Transfer of lipids, metabolites, Ca2+ and peptides by chaperones facilitate the cross-talk between the 
ER and mitochondrion. Due to the inter-organelle communication, an insult to mt function elicits an 
ER response, and vice versa (Malhotra and Kaufman, 2011). The unfolded protein response (UPR) is 
part of the ER stress response and is an example of co-ordinated mt and ER stress (Senft and Ronai, 
2015). 
Endoplasmic reticulum stress is characterised as an accumulation of misfolded proteins in the lumen 
of the ER. Oxidative stress and mt dysfunction contribute to an elevation in misfolded proteins, often 
exacerbating ER stress (Xu et al., 2005, Haynes et al., 2004). The ER stress response is a cellular 
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response to restore homeostasis by two mechanisms: - 1) increasing the protein folding rate; 2) 
reducing the client protein load entering the ER. Reduction in the influx of client proteins is mediated 
by three main ER stress responses: protein kinase RNA-like ER kinase (PERK), activating 
transcription factor (ATF) 6, and inositol-requiring enzyme 1 (IRE1). The molecular mechanisms of 
these three sensors in the unfolded protein response (UPR) are described in Figure 2.11.  
 
Figure 2.11: Molecular mechanisms of endoplasmic reticulum mediated unfolded protein 
response. The PERK mediated response is an effort to reduce translation by phosphorylation of 
eukaryotic translation initiation factor 2α (eIF2α). Activating transcription factor 6 (ATF6) 
accelerates folding and packaging of proteins in the Golgi apparatus. Inositol-requiring enzyme 
(IRE1) enhances degradation of mRNA and activates stress protein c-Jun N-terminal kinase 
(JNK) and inflammatory nuclear factor kappa-light chain enhancer of activated B cells (NFκB). 
The activation of JNK amplifies the activity of eiF2α to reduce protein influx (Senft and Ronai, 
2015) 
The chaperone activity of Lon has been identified as key role player in the transmission of ER stress 
to the mitochondrion (Hori et al., 2002). Silencing of PERK prevented the induction of Lon and the 
25 
 
recruitment of heat shock protein (HSP) 60 and mt HSP70 to form a complex with Lon. Heat shock 
proteins are ATP-dependent pro-survival molecules that are ubiquitously expressed. Heat shock 
protein 60 is localized in the mitochondria and regulates protein folding and chaperoning in the mt 
matrix, as well as mtDNA assembly (Kaufman et al., 2003). The complex formed with Lon, HSP60 
and mtHSP70 is required for mt mediated cell death and protein assembly (Kao et al., 2015, Bender et 
al., 2011). The regulatory role of ER stress response proteins on the assembly of this complex 
provides a mt response to ER stress. 
 
2.5. ENDOGENOUS ANTIOXIDANT DEFENCE MECHANISMS 
The chemical modification of xenobiotics is an adaptive response to aid in the excretion of drugs. 
Phase I enzymes in biotransformation largely consist of CYP450 mono-oxygenases, which often 
produce electrophilic metabolites (Payne et al., 1987). Substrates of  CYP450 mono-oxygenases 
include AZT and 3TC (Veal and Back, 1995), to a lesser extent d4T (Kaul et al., 1999), but not TFV 
(Chittick et al., 2006). The production of CYP450 metabolites stimulate phase II enzymes, which 
facilitate the conjugation of the electrophiles to reduced glutathione (GSH) and glucuronic acid. The 
liver is central to xenobiotic metabolism due to the high expression of both phase I and II enzymes. 
Therefore the liver bears the brunt of electrophilic attack caused by xenobiotic metabolism (Park et 
al., 1995). Under these circumstances, intricately co-ordinated cellular defence mechanisms are in 
place to maintain redox status and contain oxidative damage. The endogenous antioxidant defence 
system is an indispensable component to the cytoprotective armoury. Antioxidants scavenge free 
radicals by acting as electron donors, undergoing oxidation themselves. In order for this reaction to 
occur antioxidants require reducing capabilities, e.g. thiols, polyphenols. 
2.5.1. Superoxide detoxification 
The O2•- anion radical is one of the most abundantly produced ROS from the ETC. The products of 
O2•- reactions often yield other reactive species, perpetuating oxidative insult (Sies, 1991). The first 
line of defence against O2•- is SOD. Superoxide dismutase is one of the most extensively studied 
enzymatic antioxidants. The enzyme exists in different isoforms depending on its sub-cellular 
location: SOD1 (cytosol; mitochondrion), SOD2 (mitochondrion), and SOD3 (extracellular) (McCord 
and Fridovich, 1988, Tainer et al., 1983). Superoxide dismutase converts O2•- to hydrogen peroxide 
(H2O2). Hydrogen peroxide may be rapidly converted to OH• via the Fenton reaction, and thus 




Figure 2.12: Schematic representation of the first line of defence against mitochondrial ROS 
production. Superoxide dismutase (SOD) catalyzes the reaction of O2•- to H2O2. Hydrogen 
peroxide may be further processed by catalase (CAT) or glutathione peroxidase (GPx). 
Glutathione peroxidase mediates the donation of electrons from reduced glutathione (GSH) to 
convert H2O2 to H2O. Oxidized GSH (GSSG) may be converted back to the reduced state by 
glutathione reductase –GR (Figure by author) 
2.5.2. Glutathione antioxidant defence 
The GSH mediated antioxidant response is one of the most important phase II detoxification pathways 
in drug metabolism (Figure 2.12). The thiol groups present in GSH give this antioxidant its biological 
activity. The sulfhydryl groups act as proton donors, converting disulphide bonds in oxidized proteins 
to cysteine. Two GSH molecules may also react with H2O2 to yield water and oxidized GSH (GSSG) 
in a reaction catalysed by GPx (Wendel, 1980). Reduced glutathione may be regenerated by 
acceptance of an electron from NADPH. The regeneration of GSH is mediated by the activity of 
glutathione reductase (GR). Depletion of GSH is often regarded as an indicator of cytotoxicity (Arrick 
and Nathan, 1984). Selenium is necessary for GPx activity, thus its depletion compromises the 
antioxidant response (Rotruck et al., 1973). 
2.5.3. Master regulator of antioxidant response - Nuclear factor erythroid 2-related factor 2 (Nrf2) 
Stress responses, including antioxidant defence, require rapid response and tightly regulated systems. 
The antioxidant response element (ARE) is a cis-acting element that is located either on the promoter 
or upstream of the promoters of major phase II and antioxidant genes (Kobayashi and Yamamoto, 
2006). Transcriptional induction of the ARE allows for the expression of a battery of cytoprotective 
genes including GPx, thioredoxin, SOD, heme-oxygenase 1 (HO-1), peroxidases and glutathione-S-
transferase. Since the identification of the ARE, the role of the nuclear-erythroid 2-related factor 2 
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(Nrf2)/ Kelch-like erythroid cell derived protein with CNC homology (ECH)-associated protein 
(Keap1) pathway in cellular defence has become a focus in antioxidant research.  
 
Figure 2.13: The initiation of antioxidant stress response by Nrf2. Upon oxidation of cysteine 
residues binding the Nrf2/Keap1 complex, Nrf2 translocates to the nucleus and forms a 
homodimer with a small Maf protein. Following recognition of a consensus sequence, the 
Nrf2/Maf complex binds to the ARE and induces the transcription of antioxidant defence and 
transporter genes. Under normal conditions, Nrf2 is marked for degradation by the ubiquitin 
proteasome (Huang et al., 2015) 
Nuclear-erythroid 2-related factor 2 is a basic region leucine zipper (bZIP) transcription factor that 
belongs to the Cap ‘n’ Collar (CNC) family (Moi et al., 1994). Tissue involved in detoxification 
(liver, kidney) and organs with exposure to the external environment (lungs, skin, gastrointestinal 
tract) have elevated expression of Nrf2 (Copple et al., 2008). The mechanism by which Nrf2 induces 
transcription of the ARE is shown in Figure 2.13. Under normal conditions, Nrf2 is bound to its 
inhibitor Keap1 in the cytoplasm (Itoh et al., 1997) and is marked for degradation by the ubiquitin 
proteasome. An increase in electrophiles, however, causes oxidation of the cysteine residues that 
tether Nrf2 to Keap1 (Stewart et al., 2003). The free Nrf2 undergoes phosphorylation at the 
transactivation domain, and subsequently translocates to the nucleus. At the nucleus, Nrf2 recognizes 
the ARE and through heterodimerisation with small Maf proteins, binds to the ARE, initiating 
transcription of antioxidant genes (Motohashi and Yamamoto, 2004). 
The importance of Nrf2 in protection against drug induced cytotoxicity has been well established 
(Copple et al., 2008). Although the classical implication of Nrf2 in cellular defence is related to 
antioxidant induction, alternative roles of the transcription factor are quickly emerging. The binding 
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of Nrf2 to the ARE is mediated by recognition of a consensus sequence (Figure 2.13). The ARE, 
however, shares motifs with the mt biogenesis regulator, NRF1. Due to these shared motifs, Nrf2 has 
been shown to interact with NRF1, mediating mt biogenesis (Piantadosi et al., 2008). A role for Nrf2 
in metabolic reprogramming has also been identified (Mitsuishi et al., 2012). An interesting concept 
that has yet to gain momentum is the role of Nrf2 in xenobiotic detoxification via induction of drug 
transporters (Aleksunes et al., 2008, Maher et al., 2005). The diverse protective activity of Nrf2 is an 
important cytoprotective response in drug-induced toxicity. 
 
2.6. DETOXIFICATION BY ATP-DEPENDENT EFFLUX DRUGS TRANSPORTERS 
Drug metabolizing enzymes and transporters are determinants of drug efficacy, toxicity and excretion. 
Charged or polar drugs are unable to passively cross cell membranes. (Doring and Petzinger, 2014). 
Two major drug transporter families are important: solute carrier proteins (influx) and ATP-binding 
cassette (ABC) proteins (efflux). The role of these transporters in drug metabolism and processing is 
regarded as phase 0 and phase III respectively. Phase III proteins aid in reducing the risk of 
bioaccumulation of xenobiotics. 
2.6.1. ATP-binding cassette family of transporters 
The ABC super-family of transporters are energy dependent membrane proteins that actively transport 
both endogenous and pharmacological agents, including anti-cancer and anti-viral drugs. The ABC 
proteins have a commonality in structure, consisting of a transmembrane domain (TMD) and 
nucleotide binding domain (NBD). The TMD spans the membrane and varies among subtypes of ABC 
proteins. This domain is responsible for the recognition of substrates and undergoes a conformational 
change to facilitate transport of the substrate across the cell membrane. The NBD, which is essentially 
the “ATP-binding cassette”, contains a catalytic core and an α-helical subdomain (Vasiliou et al., 
2009). Hydrolysis of ATP in the catalytic core enables the TMD to undergo conformational change. 
The 49 ABC genes that have been identified are subcategorized into seven families (ABCA; ABCB; 
ABCC; ABCCD; ABCCE; ABCCF; ABCCG). Each family codes for protein transporters known under 
different names. The ABCC class of transporters code for multi-drug resistance proteins (MRPs); this 
transporter was first recognized for conferring resistance to chemotherapeutic agents (Yokoyama et 
al., 1999, Chan et al., 1997, Stavrovskaya and Stromskaya, 2008).  
2.6.2. Multi-drug resistance proteins 
There are twelve classes of MRPs (MRP1-MRP12), all coded for by respective ABCC genes. Multi-
drug resistance proteins mediate energy dependent efflux of xenobiotic compounds, lowering the 
intracellular concentration. The substrate range of MRPs is broad, including prostaglandins (Reid et 
al., 2003), bile salts and conjugates, steroids (Zelcer et al., 2003), glutathione conjugates (Rius et al., 
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2003), cyclic nucleotides (Wielinga et al., 2003), antiviral drugs:- TFV and Adefovir (Imaoka et al., 
2007), antihypertensive drugs:- furosemide and hydrochlorothiazide (Hasegawa et al., 2007), and 
anticancer drugs:- camptothecin (Tian et al., 2005), methotrexate (Chen et al., 2002), and topotecan 
(Tian et al., 2006). The major MRPs involved in detoxification are those expressed in the liver and 
kidney. These include MRP2, MRP4 and MRP5 (Keppler, 2011, Ritter et al., 2005).The unique ability 
of MRP4 (coded for by ABCC4) to transport cyclic nucleotides, antiviral drugs and their metabolites 
is of relevance to NRTI clearance from hepatocytes. 
2.6.3. Multi-drug resistance protein 4 (ABCC4) 
Multi-drug resistance protein 4 is expressed in renal tubules, capillaries in the brain, blood cells and 
the basolateral membrane of hepatocytes (Ritter et al., 2005). The protein was first reported in T-
lymphoid cells and was associated with resistance to nucleoside analogues used in HAART, including 
AZT and d4T (Schuetz et al., 1999). The protein quickly gained notoriety for drug resistance, 
however, the ability of MRP4 to transport nucleotides, conjugated steroids and ADP showed MRP4 
was also involved in cell signalling (Sellers et al., 2012, Sinha et al., 2015, Russel et al., 2008). The 
high expression of ABCC4/MRP4 in the liver and kidney has also led to the assumption MRP4 may 
reduce the risk of xenobiotic bioaccumulation at drug deposition sites. This idea is reiterated by the 
induction of MRP4 by stress response transcription factor, Nrf2 (Maher et al., 2008, Satoh et al., 
2013). 
Expression of MRP4/ABCC4 is variable, with poor correlations between mRNA and protein levels 
(Markova and Kroetz, 2014). The ABCC4 gene is highly polymorphic and studies have evaluated the 
effect of different single nucleotide polymorphisms on the expression and activity of MRP4 (Abla et 
al., 2008, Kelly et al., 2010, Markova and Kroetz, 2014). Differences in the DNA sequence of the 
ABCC4 promoter, however, do not entirely account for the regulation of gene expression. A recent 
study by Markova and Kroetz (2014) reported a novel epigenetic mechanism of ABCC4 modulation 
by microRNA (miR-) 124a and miR-501 (Markova and Kroetz, 2014). 
2.6.4. MicroRNA and drug transporters 
MicroRNA (miRNAs) are an abundant class of short non-coding RNA that fall under the field of 
epigenetics. Epigenetics refers to genomic modifications independent of changes to the actual gene 
sequence. Examples of epigenetic modifications include DNA methylation, chromatin and histone 
modification and miRNAs. MicroRNAs are 18-25 nucleotides long and play a role in post-





Figure 2.14: Mechanism of microRNA (miRNA) biogenesis and mode of RNA silencing. 
MicroRNAs can be generated from either their own genes or the introns of protein-coding genes 
and are transcribed as independent units. Transcription of miRNA is carried out by RNA 
polymerase II (Pol II), producing large capped primary transcripts (Pri-miRNA). Primary 
transcripts are characterized by stem loops. The RNA III enzyme, Drosha, together with its co-
factor (Pasha) cleave pri-miRNA at the stem of the loop, releasing 70-nucleotide long pre-
miRNA products. The nuclear transporter, Exportin 5, and GTPase Ran facilitate the export of 
the pre-miRNA from the nucleus to the cytoplasm. In the cytoplasm, pre-miRNA is subject to 
further processing by Dicer, producing a miRNA duplex. The duplex is loaded into an RNA-
inducing silencing complex (RISC), consisting of multiple proteins, including Argonaute 
proteins. Mature miRNA are unwound and remain tethered to Argonaute proteins within the 
complex. MicroRNA have more than one target gene. The mature miRNA binds the 3’ 
untranslated region (UTR) of the target gene, under the guidance of Argonaute protein, by 
complementary base pairing. Perfect complementarity with a target gene results in degradation 
of the target mRNA. Imperfect complementarity causes translational repression (Esquela-
Kerscher and Slack, 2006) 
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MicroRNA have been implicated in various biological processes and pathological conditions 
including cancer (Jansson and Lund, 2012), diabetes (McClelland and Kantharidis, 2014), 
cardiovascular disease (Small et al., 2010) and recently drug transport and metabolism (Peng and 
Zhong, 2015). The regulatory role of miRNAs on ABC transporters has been confirmed in 
hepatocellular carcinoma. Thirteen miRNAs are associated with the modulation of gene expression of 
ABCA1, ABCC1, ABCC5, ABCC10, and ABCE1 (Borel et al., 2012). The transporter ABCC1 is 
regulated by miR-1291 in pancreatic cancer (Pan et al., 2013) and miR-134 in breast cancer cells (Lu 
et al., 2015). Multi-drug resistance protein 1 (coded for by ABCC1) was also found to be negatively 
regulated by miR-27a and miR-451 (Zhu et al., 2008). The majority of these studies have focussed on 
cancer and chemotherapeutic agents. The impact of miRNA regulation in determining drug toxicity 
through cellular transporters will have significant implications for long term therapies such as 
HAART. 
The adverse health outcomes of long term NRTI (lipodystrophy, metabolic syndrome, 
cardiomyopathy, neuropathy, renal dysfunction) can all be related to mt dysfunction. Although mt 
toxicity has been established as a mechanism of NRTI toxicity, there are still gaps in the knowledge 
of molecular events that lead to adverse clinical outcomes. The effects of NRTI use on redox status, 
antioxidant response, mitochondrial biogenesis and cellular detoxification mechanisms is still not 
clearly defined. Furthermore, the epigenetic modulation of these processes in relation to NRTI 
toxicity is also not widely known. Investigations into the biochemical outcomes of acute and 
prolonged exposure at plasma level concentrations will provide physiologically relevant insight and 
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Chronic HIV treatment with antiretroviral drugs has been associated with adverse health outcomes. 
Mitochondrial toxicity exhibited by nucleoside reverse transcriptase inhibitors (NRTIs) is pinpointed 
as a molecular mechanism of toxicity. 
This study evaluated the effect of NRTIs: Zidovudine (AZT, 7.1µM), Stavudine (d4T, 4µM) and 
Tenofovir (TFV, 1.2µM), on mitochondrial (mt) stress response, mtDNA integrity and oxidative 
stress response in human hepatoma cells at 24h and 120h. Markers for mt function, mt biogenesis, 
oxidative stress parameters, and antioxidant response were evaluated by spectrophotometry, 
luminometry, flow cytometry, qPCR and western blots.  
We found that AZT and d4T reduced mtDNA integrity (120h, AZT: 76.1%; d4T:36.1%, p<0.05) and 
remained unchanged with TFV. All three NRTIs, however, reduced ATP levels (AZT: 38%; d4T: 
56.4%; TFV: 27.4%-, p=0.01) and mt membrane potential at 120h (p<0.005). Oxidative damage and 
reactive oxygen species were increased by TFV and AZT at 24h, and by d4T at 120h (p<0.05). 
Antioxidant response molecules and mt biogenesis markers were elevated by all NRTIs, with TFV 
causing the most significant increase (p<0.05). 
Data from this study suggests that AZT, d4T and TFV alter mt function. TFV, however, achieves this 
independently of mtDNA depletion. Furthermore, AZT exerts toxicity soon after exposure as noted 





Nucleoside reverse transcriptase inhibitors (NRTIs) form the backbone of combination antiretroviral 
therapy in HIV treatment. In developing countries, the massive rollout of these drugs favour 
standardized fixed dose combinations due to limited resources and cost effectiveness. Under these 
circumstances, the long term use of these drugs has seen the emergence of adverse health outcomes, 
particularly changes to metabolic parameters, lipodystrophy, dyslipidemia and hepatic steatosis [Carr 
and Cooper, 2000]. Investigation into antiretroviral therapy and their associated disorders found 
individual NRTIs had varying degrees of toxicity that are tissue specific and time dependent [Birkus 
et al., 2002; Bleeker-Rovers et al., 2000; Igoudjil et al., 2007; Kline et al., 2009]. 
Mitochondrial (mt) toxicity is a common outcome of NRTI use. Initially, thymidine analogues, 
including Zidovudine (AZT) and Stavudine (d4T), were considered to be the main culprits due to the 
inhibitory effect of these drugs on mtDNA replication [Brinkman et al., 1998]. However, other 
NRTIs, such as Tenofovir (TFV), still exhibit mt toxicity in spite of maintaining mtDNA levels 
[Kohler et al., 2009; Lebrecht et al., 2009]. This opened up investigations into alternate mechanisms 
of mt toxicity. Other proposed targets of NRTI toxicity include ATP synthesis, mt biogenesis, 
depleted native nucleotide pools, transcription of mtDNA, mt membrane integrity and transport and 
protein synthesis [Cohen, 2010; Setzer et al., 2008]. 
Oxidative stress and mt dysfunction are two closely linked outcomes of xenobiotic metabolism. 
Disruptions to mt function increase the production of reactive oxygen species (ROS), especially 
superoxide (O2•-), via defective oxidative phosphorylation. Elevated free radical production over a 
period of time depletes the antioxidant defence response, eventually resulting in oxidative damage to 
bio-macromolecules including DNA, protein and lipid membranes. 
The antioxidant defence system is regulated by the transcription factor, nuclear factor erythroid 2-
related factor 2 (Nrf2). Nrf2 exists in the cytoplasm, bound to its inhibitor, Kelch-like associated 
ECH-associated protein (Keap1). In this state, Nrf2 is marked for degradation by ubiquitin, 
maintaining Nrf2 at low basal levels. Elevated ROS levels cause dissociation of Nrf2 from Keap1 by 
oxidizing the cysteine residues of the Nrf2-Keap1 complex. This allows Nrf2 to translocate to the 
nucleus and bind to the antioxidant  response element (ARE), initiating the transcription of 
antioxidant (AO) genes such as superoxide dismutase (SOD), glutathione peroxidase (GPx), 
glutathione reductase, and catalase [Motohashi and Yamamoto, 2004]. Aside from the endogenous 
antioxidant defence system, repair mechanisms are in place to compensate for oxidative damage. The 
high affinity for ROS to the guanine base in DNA results in DNA mutations and lesions. A base 
excision repair response to both nuclear and mtDNA damage is modulated by the enzyme, 8-
oxoguanine DNA glycosylase (OGG1) [Stuart et al., 2004]. 
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Mitochondria, being the main endogenous source of ROS, also require specialized defence 
mechanisms. An inner mitochondrial membrane protein, uncoupling protein2 (UCP2), is one such 
mechanism that functions to reduce ROS production by uncoupling oxidative phosphorylation from 
ATP synthesis. It achieves this by increasing proton conductance across the inner mt membrane, thus 
reducing ROS production during ATP synthesis [Nedergaard et al., 2005]. A common observation of 
mt toxicity is the up-regulation of mt biogenesis markers. The transcription of mt genes and mt 
biogenesis is regulated by a transcription co-activator, peroxisome proliferator-activated receptor γ co 
activator 1α (PGC-1α). PGC-1α regulates mt gene transcription via interaction with nuclear 
respiratory factor 1(NRF1) and 2, which in turn activates mt transcription factor A (TFAM) [Mallon 
et al., 2005]. Previous studies found that both PGC-1α and TFAM expression was elevated in the 
presence of NRTIs, suggesting a nuclear response to mt toxicity [Mallon et al., 2005; Setzer et al., 
2008]. Aside from its role in mt biogenesis, PGC-1α also acts as a modulator of mt AO response by 
increasing expression of oxidative stress protective genes [St-Pierre et al., 2006; Valle et al., 2005]. 
Mitochondrial AO responses such as PGC-1α and UCP2 are of importance as a known outcome of 
NRTI toxicity is oxidative stress [Lewis et al., 2001; Manda et al., 2011]. 
Naturally, the nature of NRTI toxicity results in mitochondria-rich tissues being the most affected 
following chronic exposure [Dagan et al., 2002]. The liver being the metabolic hub of humans is 
abundant in mitochondria. The HepG2 cell line has been widely used in previous studies evaluating 
the effect of antiretroviral drugs on mitochondrial toxicity [Birkus et al., 2002; de Baar et al., 2007; 
Setzer et al., 2008; Velsor et al., 2004; Walker et al., 2002]. HepG2 cells possess cytochrome P450 
activity and has hence been identified as an early  model for xenobiotic metabolism [Roe et al., 1993]. 
Nucleoside reverse transcriptase inhibitors, including AZT and d4T, require intracellular 
phosphorylation to their triphosphate active form. It is only in this form that the drugs may 
incorporate into DNA, exerting an effect.  The cytochrome P450 activity of HepG2 cells is integral to 
the biotransformation of NRTIs. This study aimed to investigate the effects of three commonly used 
NRTIs: AZT, d4T and TFV on mt function and AO response; focussing on Nrf2 and PGC-1α 
mediated stress responses, in HepG2 liver cells following exposure for 24 hours (h) and 120 h.  
Materials and Methods 
Materials 
All reagents were purchased from Merck (Darmstadt, Germany), unless otherwise stated. Cell culture 
media were obtained from Lonza, Biowhittaker (South Africa), and supplements were purchased from 
Sigma-Aldrich (St Louis, MO, USA). All antiretroviral drugs were obtained from the NIH Aids 
reagents programme. Antibodies utilized for western blots were purchased from Cell Signalling 




Cell culture and treatment 
Human hepatoma (HepG2) cells were cultured in supplemented Eagle’s minimum essential media 
(10% foetal calf serum, 1% penstrepfungizone, 1% L-glutamine) at 37°C in a humidified incubator. 
Cells were seeded in sterile 25cm3 cell culture flasks and subject to treatment once the cells were 80% 
confluent.  
Stocks of NRTIs (10mM in dimethylsulphoxide) were prepared. HepG2 cells were treated with 
NRTIs at maximum plasma level concentrations [Venhoff et al., 2007; Walker et al., 2002]. 
Treatments with AZT (7.1µM), d4T (4µM), TFV (1.2µM) and an untreated control were conducted 
over two time periods (24 h; 120 h). For the 120 h treatment, fresh cell culture medium containing 
NRTI treatment was replenished every 48 h. 
Lipid peroxidation 
Lipid peroxidation was used as a marker of oxidative stress. The thiobarbituric reactive substances 
(TBARS) assay was used to quantify extracellular malondialdehyde (MDA), a by-product of lipid 
peroxidation. Following treatments, 2 ml of supernatant from each treatment was aspirated and freeze 
dried. The lyophilized supernatants were then reconstituted in 500µl of 0.1M phosphate saline buffer 
(PBS) and used for the TBARS assay. The TBARS assay was conducted as per the method described 
by Phulukdaree et al., 2010 [Phulukdaree et al., 2010]. Absorbance of the samples was read using a 
spectrophotometer, λ = 532/600nm (Bio-Tek µQuant, Winooski, VT, USA). MDA concentrations 
(mM) were calculated by dividing the mean absorbance of the samples by the absorption coefficient 
(156mM-1). 
Intracellular reactive oxygen species 
Intracellular ROS (Superoxide: O2•-, hydrogen peroxide, peroxynitrite) was quantified by fluorescence 
activated cell sorting (FACS) using the fluorescent probe, 2′,7′-dichlorodihydrofluorescein diacetate 
(H2DCF-DA). Following exposure to NRTIs (24 h, 120 h), 1 x 106 HepG2 cells were incubated in 
phenol red-free media supplemented with 10% foetal calf serum and 10µM H2DCFA for 45 min at 
37oC.The probe diffuses into the cell and is retained intracellularly, until it is cleaved by intracellular 
esterases to the non-fluorescent 2’,7’-dichlorodihydrofluorescein (H2DCF). Intracellular ROS oxidize 
H2DCF to 2',7'-dichlorofluorescein (DCF) which emits fluorescence at 525nm. Stained cells were 
rinsed thrice with 0.1M PBS (400 x g, 5min, RT) and resuspended in 150µl of 0.1M PBS. 
Fluorescence of 20 000 events was measured using the FL-1 channel (525nm) of the AccuriTM C6 
flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA). Live cells were gated using 







The percentage mitochondrial depolarisation (Δψm) was measured using FACS and the JC-1 
Mitoscreen (BD Biosciences, San Jose, CA, USA). Briefly, JC-1 stock solution was diluted in 1X 
Assay Buffer (37°C) to make up a working solution. Approximately 200,000 cells suspended in 100µl 
of 0.1M PBS from each treatment were transferred to 1.5ml tubes containing 100µl of JC-1 staining 
solution and incubated (10 min, 37°C). Thereafter, 100µl of FACS sheath fluid was added to each 
sample. Flow cytometry data from stained cells (50 000 events) was captured with the Accuri™ C6 
flow cytometer and software (BD Biosciences, San Jose, CA, USA). Live cells were gated using 
CFlow Plus Software (BD Biosciences, San Jose, CA, USA). 
Reduced and total glutathione 
The endogenous antioxidant, reduced glutathione (GSH) was measured by the GSH-GloTM 
Glutathione Assay (Promega, Madison, USA) as per the manufacturer’s instructions. Both reduced 
glutathione (GSH) and a total of reduced and oxidized glutathione (GSSG) were quantified. The total 
amount of glutathione present (GSH+GSSG) was quantified by addition of Tris-(2-carboxyethyl)-
phosphine (TCEP) which reduces GSSG to GSH.  
Briefly, 6 GSH standards were prepared (0µM - 50µM) to derive a standard curve. 50µl of cell 
suspension (20,000 cells)/standard solution was aliquot in a white microtitre plate. For the 
quantification of GSH+GSSG, 10µM of TCEP was added per well. Thereafter, 50µl GSH-GloTM 
Reagent (1µl Luciferin-NT, 1µl Glutathione-S-transferase, 48µl GSH-GloTM Reaction buffer) was 
added per well and incubated for 30 min. Luminescence was measured on a ModulusTM microplate 
luminometer (Turner BioSystems, Sunnyvale, USA). 
ATP 
ATP was measured by the luminometric Cell Titer-Glo® assay. Cells were aliquoted in a white 
microtitre plate (20,000 cells per well) in a 1:2 ratio with ATP Cell Titer-Glo® Reagent (Promega, 
Madison, USA). The plate was incubated for 30 min at RT. Luminescence was measured on a 
ModulusTM microplate luminometer (Turner BioSystems, Sunnyvale, USA). Luminescence is 
proportional to ATP concentration and was expressed as relative light units (RLU). 
RNA isolation and quantitative PCR 
Complementary DNA (cDNA) was synthesized from RNA for quantitative PCR (qPCR). Total RNA 
was isolated using an in-house protocol [Chuturgoon et al., 2014]. RNA concentrations were 
determined (Nanodrop 2000, ThermoScientific, South Africa) and standardised to a concentration of 
1, 000ng/µl. RNA was then converted to cDNA using the iScriptTM cDNA Synthesis kit (BioRad; 
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catalog no. 107-8890). A reaction volume of 20µl containing 4µl of 5X iScript reaction mix, 1µl of 
iScript reverse transcriptase and 2, 000ng of RNA template were made up in nuclease free water. 
Thermocycler conditions for cDNA synthesis were 25°C for 5 min, 42°C for 30 min, 85°C for 5 min 
and a final hold at 4°C. 
Gene expression of oxidative DNA damage response (OGG1) and mitochondrial transcription 
(TFAM) were determined by qPCR. The iQTM SYBR® Green Supermix (BioRad, 170-880) was used 
to measure mRNA levels of the genes of interest. Briefly 1.5µl of cDNA template was added to 1µM 
of sense primer (TFAM: 5'-TATCAAGTGCTTATAGGC-3' ;OGG1: 5’-
GCATCGTACTCTAGCCTCCAC-3’), 1µM antisense primer (TFAM: 5'-
CACTCCTCAGCACCATATTTCG-3';OGG1: 5’-AGGACTTTGCTCCCTCCAC-3’), 5X iScript 
reaction mix and nuclease free water in a final reaction volume of 25µl. Initial denaturation was 
conducted at 95°C for 4 min, followed by 37 cycles of denaturation (95°C; 15 sec), annealing [50°C 
(TFAM)/60°C (OGG1); 40 sec], and extension (72°C; 30 sec). 
All qPCR experiments were conducted on the CFX96 TouchTM Real-Time PCR Detection System 
(BioRad). Changes to gene expression were calculated according to the methods described by Livak  
and Schmittgen [Livak, 2001]. Results are converted from mean relative fold change (2-∆∆Ct) to 
percentage mRNA expression relative to the untreated control (100%). A minimum of three 
housekeeping genes, β-Actin (sense: 5'-TGACGGGTCACCCACACTGTGCCCAT-3'; antisense: 5'-
CTAGAAGCATTTGCGGTGGACGATGGAGGG-3'); GAPDH: (sense: 5’-
TCCACCACCCTGTTGCTGTA-3’; antisense: 5’-ACCACAGTCCATGCCATCAC-3’); 18S: (sense: 
5’-ACAGGGACAGGATTGACAGA-3’; antisense: 5’-CAAATCGCTCCACCAACCTAA-3’) was 
amplified simultaneously under the same conditions. 
Mitochondrial DNA viability 
DNA was isolated from cell suspensions as described by Sambrook [Sambrook and Russell, 2001]. 
Isolated DNA was quantified using the Nanodrop 2000 spectrophotometer and standardized to 5ng/µl. 
A reaction volume of 25µl consisting of 12.5µl SYBR Green Supermix (BioRad, Hercules, CA, 
USA), 10pmol of forward (5’-TGAGGCCAAATATCATTCTGAGGGC-3’) and reverse primer (5’-
TGCACCTGCTCTCTGTGATTATGACTATCCCACAGTC-3’), and ~10ng DNA template made up 
in nuclease free water. Changes in mtDNA application were calculated based on the method described 
by Livak and Schmittgen, 2001 [Livak, 2001] and reported as percentage mtDNA amplification 
relative to untreated control (100%). A house keeping gene, β-Globin (sense: 5’-
ACATGATTAGCAAAGGGCCTAGCTTGACTCAGA-3’; antisense: 5’-
TGCACCTGCTCTGTGATTATGATATCCCACAGTC-3’) was amplified simultaneously. Initial 
denaturation was applied (94°C; 3 min), followed by 28 cycles of denaturation (94°C; 20 sec); 
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annealing (58°C; 10 min), extension (72°C; 10 min) and a plate read. This was followed by a melt 
curve and a final hold (25°C; 5 min). 
Western blots 
Protein expression of PGC-1α, Nrf2, UCP2 and SOD1 were determined using western blots. Briefly, 
200µl of Cytobuster (Novagen, San Diego, CA, USA) supplemented with protease and phosphotase 
inhibitors (Roche, Mannheim, Germany) was added to treated cells in cell culture flasks and kept on 
ice for 30 min before being scraped and transferred to 1.5ml tubes. The cell lysates were centrifuged 
(13,000 g, 10 min). Crude protein was quantified using the bicinchoninic assay. All protein samples 
were standardised to 2mg/ml. Laemmeli buffer [dH2O, 0.5M Tris-HCl (pH 6.8), glycerol, 10% SDS, 
β-mercaptoethanol, 1% bromophenol blue] was added to the samples (1:1 ratio) and boiled for 5 min. 
Samples were separated by electrophoresis on a SDS polyacrylamide gel (4% stacking, 10% 
resolving) for 1 h at 150 V. The separated proteins were transferred to a nitrocellulose membrane 
using the TransBlot Turbo Transfer System (BioRad, Hercules, CA, USA) at 400mA for 45 min. 
Membranes were incubated in a blocking solution of 5% bovine serum albumin (BSA) in Tween 20-
Tris buffered saline (TTBS) for 1 h; at RT. The membranes were incubated with primary antibody 
[mouse anti-SOD1 (CS4266), rabbit anti-Nrf2 (ab31163), goat anti-UCP2 (ab77363), rabbit anti-
PGC-1α (CS2178), 1: 1 000 dilution in 1% BSA] for 1 h; at RT, and then overnight at 4°C. The 
membranes were washed five times with TTBS (10 min) before being incubated in HRP-conjugated 
secondary antibody [goat anti-mouse (31800); goat anti-rabbit (ab6112) 1:10 000 in 1% BSA] for 1 h; 
at RT. The membranes were then washed 5 times in TTBS (10 min). Clarity Western ECL Substrate 
(BioRad, Hercules, CA, USA) detection reagent was used to visualise protein bands. Images were 
captured using gel documentation system Alliance 2.7 (UviTech, Cambridge, UK). Relative band 
density (RBI) was measured by densitometric analysis using UViTech Alliance Analysis software. 
Membranes were stripped with 5% hydrogen peroxide, incubated in blocking solution (3% BSA; 1 h; 
RT), rinsed twice in TTBS and probed with HRP-conjugated antibody for the house-keeping protein, 
β-actin (Sigma, St Louis, MO, USA). The relative band intensity was normalised against β-Actin and 
then reported as fold change relative to the control. 
 Statistical analysis 
Statistical analyses were performed using the GraphPad Prism V5 software package (GraphPad 
Software Inc., San Diego, California, USA). All data sets were assessed for Gaussian distributions 
using the D'Agostino & Pearson omnibus normality test. Comparisons between the control and drug 






Oxidative damage and intracellular antioxidant levels 
HepG2 cells exposed to AZT and TFV for 24 h had higher levels of intracellular ROS (Figure 3.1A; p 
= 0.02) and MDA levels (p = 0.02; Figure 3.1B) relative to the untreated control. In the same time 
period, no significant changes were  observed in the intracellular ROS and MDA levels of cells 
exposed to  d4T (p>0.05). Following 120 h exposure, all three drugs increased both intracellular ROS 
(Figure 1A) and extracellular MDA levels (Figure 3.1B) compared to the control. Intracellular ROS 
levels were significantly higher in the TFV treated cells at 120 h (p = 0.02), and d4T caused the 
greatest increase in MDA levels (p = 0.02). 
At 24 h, base excision repair response, OGG1, was down-regulated in all treatments, most so in the 
AZT and d4T treatment (p < 0.0001; Table 3.1). However, after 120 h, all three NRTIs increased 
OGG1 mRNA levels relative to the control (Table 3.1). Most notably there was a 10-fold increase in 
the d4T and TFV treatments (p = 0.0003). 
After 24 h exposure, AZT increased both GSH (p = 0.04, Figure 3.1C) and GSH+GSSG (p = 0.02, 
Figure 3.1D) levels relative to the control. In the same time period, d4T reduced both GSH (Figure 
3.1C) and GSH+GSSG (Figure 3.1D). HepG2 cells exposed to TFV for 24 h showed lowered GSH 
levels (Figure 3.1C) but GSH+GSSG levels remained similar to the control (Figure 3.1D). After 120 
h, GSH levels were higher in the NRTI treated HepG2 cells than the untreated control. This, however, 
was not statistically significant (p = 0.06; Figure 1B). Total glutathione (GSH+GSSG) was only 
increased by TFV at 120 h (p = 0.02; Figure 3.1D), whilst AZT and d4T decreased GSH+GSSG 




Figure 3.1: Intracellular reactive oxygen species measured as DCF fluorescence (A), 
extracellular malondialdehyde levels (B), GSH (C) and total glutathione (GSH+GSSG; D) in 
HepG2 cells treated with NRTIs at 24 h and 120 h, *p < 0.05 relative to control 
 
Figure 3.2: ATP levels (A) and mitochondrial (mt) depolarisation (B) in HepG2 cells treated 
with Zidovudine (AZT), Stavudine (d4t) and Tenofovir (TFV) at 24 h and 120 h, *p < 0.05 




Mitochondrial integrity and function 
Mitochondrial membrane depolarisation and ATP were measured as mt function parameters. At both 
time periods, AZT and TFV markedly reduced ATP levels (24 h: p = 0.0.1; 120 h: p = 0.02, Figure 
3.2A) with a concomitant increase in Δψm (24h: p = 0.12; Figure 3.2B; 120 h: p = 0.02; Figure 3.2B). 
ATP levels remained unchanged at 24 h in the d4T treatment, but a marked decline was observed at 
120 h (p < 0.05). Percentage Δψm was elevated in HepG2 cells exposed to d4T for 24 h, but not 
significantly (p = 0.02; Figure 3.2B).  
The mt response to O2•- production was evaluated by quantifying UCP2 expression. At 24 h, UCP2 
protein expression increased in the AZT [1.75 RBI (Inter-quartile range: IQR: 1.70, 1.81)] and d4T 
treatment [1.80 RBI (IQR: 1.60, 2.18)] relative to the control [1.49 RBI (IQR: 1.26, 1.74); Figure 3.3]. 
The 120 h treatment showed an increase in UCP2 expression in the NRTI treated cells [Control: 1.37 
RBI (IQR: 1.20, 1.58); AZT: 1.53 RBI (IQR: 1.42, 1.68); d4T: 1.74 RBI (IQR: 1.63, 1.93)], with a 
significant increase in the TFV treatment [2.02 RBI (IQR: 1.87, 2.15); p = 0.04; Figure 3.3]. 
Protein expression of PGC-1α, a regulator of mt biogenesis, was assessed as a response to mt damage, 
while TFAM mRNA levels evaluated mtDNA transcription. The qPCR results showed that TFAM 
mRNA levels at 24 h was not differentially regulated in the TFV and AZT treatments (Table 3.1). 
Stavudine, however, significantly reduced TFAM mRNA levels at 24 h (p = 0.003; Table 3.1). 
Following 120 h exposure, TFAM mRNA levels increased in all NRTI treated HepG2 cells exceeding 
2 fold (p < 0.0001; Table 3.1). Expression of PGC-1α protein was also elevated by all three NRTIs at 
both 24 h [AZT: 3.24 RBI (IQR: 3.16, 3.33); d4T: 4.44 RBI (IQR: 4.21, 4.76)] and 120 h [AZT: 2.7 
1RBI (IQR: 2.51, 2.91); d4T: 2.94 RBI (IQR: 2.30, 3.40)] compared to their respective controls 
[Control 24 h: 2.57 RBI (IQR: 2.19, 2.96); Control 120 h: 2.01 RBI(IQR: 1.89, 2.10)]. Tenofovir 
induced significantly higher expression of PGC-1α in both time periods [24 h: 7.38 RBI (IQR: 6.69, 
8.11); p = 0.02; 120 h: 4.32 RBI (IQR: 4.0, 4.63); p = 0.02; Figure 3.3]. 
The amount of viable mtDNA in each treatment was determined by qPCR. This assay works on the 
principle that viable mtDNA levels will be proportional to mtDNA amplification. The AZT and TFV 
treatments caused an increase in mtDNA amplification relative to the control following 24 h exposure 
(Table 3.1). The d4T treatment, however, decreased the amount of viable mtDNA in this time period 
(p = 0.04; Table 3.1). At 120 h, AZT also caused a decline in mtDNA integrity and a significant 
decrease was observed in the d4T treatment (p = 0.01). Tenofovir still exhibited increased mtDNA 





Table 3.1: Percentage regulation analysis of mRNA expression (OGG1; TFAM) and mtDNA 
amplification relative to untreated control at 24 h and 120 h treatment with NRTIs 
 
  Viable mtDNA TFAM OGG1 
24 h 
AZT 184 (168, 211) 105 (51.1, 169) 44.5 (36.5, 60.3)* 
d4T 69.56 (53.6, 84.9) 6.37 (4.51, 9.19) ** 2.98 (1.68, 3.69)*** 
TFV 151 (95.2, 251) 98.1 (82.8, 106) 56.7 (53.9, 58.23) 
120 h 
AZT 76.1 (65.3, 83.3) 830 (748, 942)*** 104 (982, 117) 
d4T 36.1 (15.0, 76.4)* 278 (264, 304) 98.1 (82.8, 106)** 
TFV 189.4 (144, 214.6) 633 (557, 740)* 1047 (980, 1170)*** 
 
Data represented as median (IQR) *p < 0.05; *p < 0.005, ***p < 0.0001 relative to control 
(100%), AZT: zidovudine, d4t: stavudine, TFV: tenofovir, mt: mitochondrial, TFAM: 
mitochondrial transcription factor A, OGG1: 8-oxoguanine DNA glycosylase 
 
Antioxidant response 
The expression of key AO proteins was measured to determine the AO response induced by NRTIs. 
At 24 h, only TFV significantly increased Nrf2 protein expression in HepG2 cells [8.40 RBI (IQR: 
7.05, 9.28); p = 0.01; Figure 3.3] compared to the control [5.26 RBI (IQR: 5.02, 5.50); Figure 3.3]. At 
120 h, however, the expression of Nrf2 was elevated by d4T [5.04 RBI (IQR: 4.63, 5.82)] and AZT 
treatments [4.68 RBI (IQR: 3.86, 5.36)] relative to the control [2.83 RBI (IQR: 2.49, 3.30)], and 
significantly up-regulated by TFV [7.22 RBI (IQR: 6.83, 7.88); p = 0.02; Figure 3.3]. 
SOD1regulates both mitochondrial and cytosolic detoxification of O2•-. Only TFV significantly up-
regulated protein expression of SOD1 at 24 h [0.34 RBI (IQR: 0.33, 0.35); Figure 3.3] and 120 h 
[6.35 RBI (IQR: 6.15, 6.72); p = 0.02; Figure 3.3] compared to the control (Figure 3.3). Stavudine 
[24h: 0.02RBI (IQR: 0.02, 0.02); 120 h: 4.18RBI (IQR: 3.54, 4.50)] and AZT [24 h; 0.02RBI (IQR: 




Figure 3.3: Densitometry analysis and western blot images for antioxidant and mitochondrial 
oxidative stress response protein expression at 24 h and 120 h treatment with NRTIs. *p < 0.05 
relative to control 
Discussion 
Liver toxicity is commonly observed in patients on long term antiretroviral therapy. No clear 
mechanism has been distinguished as individual ARVs have varying degrees of toxicity [Núnez, 
2006]. Stavudine and AZT are considered among the most hepatotoxic NRTIs [Ter Hofstede et al., 
2000; Wit et al., 2002] with TFV exhibiting very low hepatic toxicity [Birkus et al., 2002]. 
Hepatocytes possess cytoprotective mechanisms against xenobiotic insult. In this study, we assessed 
the mitochondrial and AO stress responses to NRTIs in liver cells after 24 h and 120 h exposure.  
The involvement of Nrf2 in the defence against NRTI-associated toxicity integrates two major 
mechanisms of NRTI toxicity – oxidative stress and mt toxicity. Firstly Nrf2 regulates the 
transcription of AO genes during oxidative stress response [Motohashi and Yamamoto, 2004]. 
Secondly, the ARE to which Nrf2 binds in the nucleus shares motifs with transcription factor, NRF1 
[Piantadosi et al., 2008]. This provides an overlap in the function of Nrf2 and PGC-1α, as both 
promote transcription of mtDNA via activation of NRF1. We observed that NRTIs increased Nrf2 and 
PGC-1α protein expression, most so at 120 h (Figure 3.3). Increased PGC-1α expression by NRTIs 
was also accompanied by lower ATP levels (Figure 3.2A). Reduced ATP, an indication of reduced mt 
function, favours the activation of the AMP-activated protein kinase pathway, which in turn increases 
mt biogenesis via PGC-1α and TFAM activity [Zong et al., 2002]. The upregulation of PGC-1α 
induced by NRTIs would not only promote mt biogenesis, but also increase the transcription of mt 




Of the NRTIs evaluated in our study, TFV elicited the highest AO response, with a significant 
increase in the translational regulation of Nrf2 and its downstream target, SOD1 (Figure 3.3). 
Tenofovir is considered one of the least toxic NRTIs and is commonly used in pre-exposure 
prophylaxis for HIV transmission prevention [Celum and Baeten, 2012]. At 120 h TFV increased 
intracellular ROS (Figure 3.1A) indicating early signs of mt oxidative stress. However, the strong 
antioxidant response in the TFV treated cells dampens oxidative damage so that lipid peroxidation is 
lower compared to AZT and d4T treated cells (Figure 3.1B).  
A previous study evaluating the cytotoxicity of TFV on HepG2 cells found that of five NRTIs tested, 
including AZT and d4T, TFV exhibited weak hepatic toxicity [Cihlar et al., 2002]. Furthermore, TFV 
is a weak inhibitor of DNA polymerase γ [Lewis et al., 2003], the enzyme responsible for mtDNA 
replication, and does not affect mtDNA content in HepG2 cells [de Baar et al., 2007]. Our study was 
consistent with this finding, as mtDNA levels were not depleted following 120 h exposure to TFV 
(Table 3.1). However, we still found markers for mt dysfunction in TFV treated HepG2 cells (Figure 
3.2A; 3.2B). Studies assessing mt toxicity in TFV-induced nephropathy reported mt swelling and 
structural changes to mitochondria [Abraham et al., 2013; Kohler et al., 2009]. Our present study 
found that TFV caused a shift in mt membrane potential (Figure 3.2B) which would compromise the 
integrity of the mt membrane. This can change the permeability of the mt membrane, promoting mt 
swelling. This mechanism of mt toxicity can occur independently of mtDNA depletion. 
Thymidine analogues, AZT and d4T, are inhibitors of DNA polymerase γ [Bienstock and Copeland, 
2004] and can therefore disrupt mtDNA replication. Various studies have investigated the effect of 
these two NRTIs on mt function and mtDNA in different cell lines with conflicting results. This 
suggests that AZT and d4T toxicity is tissue-specific and exposure time dependent. A study conducted 
by Banerjee et al. in 2013 reported AZT significantly increased oxidative stress markers in rat liver 
homogenates following acute exposure [Banerjee et al., 2013]. Another study comparing chronic 
exposure of endothelial cells to AZT and d4T found AZT increased oxidative stress and mt 
dysfunction, and not d4T [Kline et al., 2009]. However, work by Birkus et al. (2002) on HepG2 cells 
showed d4T was more toxic to mitochondria than AZT [Birkus et al., 2002]. Research by Velsor et. al 
(2004) on HepG2 cells corroborated that d4T exhibits mt toxicity and also induced mt oxidative stress 
[Velsor et al., 2004]. Our present work found AZT induced oxidative stress during early exposure (24 
h) but markers for oxidative stress began to decline following 120 h exposure. Stavudine, however, 
only induced oxidative damage following 120 h exposure. The significantly lowered GSH levels in 
the d4T treated HepG2 cells (Figure 3.1C) is likely to contribute to the elevated oxidative damage 
observed in this treatment. Both drugs exhibited mitochondrial toxicity (Figure 3.2A, 3.2B), but this 
was more severe in the d4T treated cells. As d4T is the more potent inhibitor of DNA polymerase γ, 
and continually decreased mtDNA levels over time (Table 3.1), this may be a contributing factor to 




Our study found that NRTIs induced both the Nrf2 and PGC-1α stress responses, and this was highest 
in the TFV treatment. All drugs exhibited mt toxicity, especially at 120 h of exposure. Tenofovir 
induced mt dysfunction without reducing mtDNA levels. The d4T treatment showed the highest 
markers for oxidative stress at 120 h and lowest levels of mtDNA viability in HepG2 cells. We can 
conclude that Nrf2 and PGC-1α are very likely to play a role in the mt and oxidative stress response to 
NRTIs. Comparatively, d4T is the most likely NRTI to exhibit hepatotoxicity following prolonged 
exposure. 
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Lon protease, an ATP dependent mitochondrial (mt) protease, is important in mt protein maintenance. 
Disruption of protein homeostasis and mt dysfunction is associated with lipodystrophy, metabolic 
syndrome and accelerated aging, and are commonly observed in patients on long term antiretroviral 
therapy. Sirtuin 3 (SIRT3) is a post-translational regulator of Lon and regulates antioxidant response. 
We previously showed the nucleoside analogues (NRTIs), Zidovudine (AZT; 7.1μM), Stavudine 
(d4T; 4μM), and Tenofovir (TFV; 1.2μM) induced oxidative stress and mt dysfunction in human 
hepatoma (HepG2) cells at 24 hours (h) and 120 h. We conducted a mt proteomic assessment of 
homeostasis in the same model, using the same NRTIs. Protein expression of Lon, SIRT3, heat shock 
protein (HSP) 60, phospho-eukaryotic translation initiation factor 2α (p-eIF2α; Ser51) and phospho-c-
jun N-terminal kinase (p-JNK; Thr183/Tyr185) were quantified by western blots. The data showed all 
stress responses were significantly increased in HepG2 cells by all antiretroviral drugs at 24 h 
(p<0.0001); however, at 120 h, a significant depletion in the ATP-dependent proteins Lon 
(p=0.00013) and HSP60 (p<0.0001) was observed. Proteins initiated by endoplasmic reticulum stress: 
p-eIF2α (p=0.001) and p-JNK (p=0.0029), were significantly reduced following prolonged treatment. 
SIRT3 was maintained at elevated levels in the treated cells following prolonged exposure (p<0.001). 
We conclude that the ATP dependent proteins are more relevant to acute toxicity, while SIRT3 
confers protection over prolonged periods of toxicity.  




Mitochondrial (mt) integrity is imperative to the optimal functioning of a biological system. 
Functionality of mitochondria is maintained by tightly regulated stress and repair mechanisms. A 
progressive decline in the efficacy of these repair and stress responses is a characteristic of biological 
aging (Hamon et al., 2015). The result of impaired stress responses is reduced mt respiratory capacity 
and increased production of free radicals, leading to oxidative stress. The highly oxidative 
environment created makes protein dense mitochondria susceptible to oxidative modification(s). 
Oxidatively modified proteins, if not cleared by proteolysis, begin to form occlusions and may result 
in aberrant structural changes to mitochondria (Ngo et al., 2013). The disruption to protein 
homeostasis in the mitochondria elicits cellular stress responses to recruit repair mechanisms and mt 
chaperones. 
Cellular proteases and chaperones are essential for the removal of misfolded or aberrant proteins. 
Proteolytic removal of oxidized proteins from the mt matrix is largely achieved by the evolutionarily 
conserved Lon protease (Lon). This mt protein, encoded for by the gene LONP1, belongs to the 
ATPases Associated with diverse cellular Activities (AAA+) protease family. Lon has the ability to 
recognise misfolded or damaged proteins by the exposed hydrophobic core of target proteins. The 
damaged protein is then proteolytically processed by Lon in an ATP-dependent manner (Gur and 
Sauer, 2008). Substrates of Lon are not exclusive to aberrant or misfolded proteins. The role of Lon in 
mtDNA turnover has been identified due to its selective degradation of mitochondrial transcription 
factor A (Lu et al., 2013; Matsushima et al., 2010). The central role of Lon in mt protein maintenance 
indicates the potential of this protein in many diseases related to mt dysfunction (Ngo et al., 2013). 
Hypoxia, oxidative stress, endoplasmic reticulum (ER) stress and ATP availability are inducers of 
Lon expression. Lon is involved in acute oxidative stress response, however, its activity cannot be 
maintained during chronic stress (Ngo et al., 2013). There have been no correlations found between 
LONP1 mRNA levels and Lon protein expression, suggesting posttranscriptional regulation of this 
protein (Gibellini et al., 2014). This is common in multiple proteins involved in stress response as it 
provides a means to increase protein turnover without the time consuming synthesis, processing and 
exportation of de novo mRNA synthesis. The posttranslational regulation of Lon by Sirtuin 3 (SIRT3) 
was recently described by Gibellini et al. (2014). Silencing of SIRT3 in breast cancer cells led to an 
accumulation of Lon protein but not LONP1 mRNA. 
The sirtuin family of NAD+ dependent deacetylases has been gaining attention for their role in 
longevity and metabolism. The mt localized SIRT3 is responsible for fat metabolism, antioxidant 
defence (Hirschey et al., 2010), mt integrity and function, and the mt unfolded protein response 
(UPRmt) (Papa and Germain, 2014). The function of SIRT3 in maintaining protein homeostasis is 
independent of the activity of the transcription factors CHOP and oestrogen receptor α. This new 
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mechanism of SIRT3 mediated UPRmt is believed to be mediated by SIRT3 antioxidant and 
mitophagy regulation (Papa and Germain, 2014). A depletion of SIRT3 is associated with accelerated 
aging-associated disorders (McDonnell et al., 2015). The overlapping role of SIRT3 and Lon in the 
maintenance of protein homeostasis is a scarcely described mechanism in acute and chronic stress 
response. 
Studies have shown Lon interacts with other mt chaperones including heat shock protein (HSP) 60, 
and mtHSP70 (Hori et al., 2002; Kao et al., 2015). Cellular chaperones such as HSPs confer resistance 
to stress conditions, promoting cell survival. The complex formed by Lon, HSP60 and mtHSP70 has 
been identified as a component in the transmission of ER stress to the mitochondria. Prolonged 
oxidative stress causes an increase in misfolded proteins which aggregate in the ER. The objective of 
the ER stress response is to inhibit or slow down protein synthesis, reducing the load of client proteins 
in the ER. Translational repression is achieved by phosphorylation of eukaryotic translation initiation 
factor 2α (eIF2α) kinase. This protein is activated by protein kinase RNA-like ER kinase (PERK) or 
c-jun N-terminal kinase (JNK). Phosphorylation of eIF2α kinase is elevated during oxidative stress 
and has been suggested as an ER response to mt stress (Baker et al., 2012). 
The long term use of nucleoside reverse transcriptase inhibitors (NRTIs) in antiretroviral therapy is 
associated with metabolic syndrome, lipodystrophy (Carr and Cooper, 2000) and accelerated aging 
(Smith et al., 2012). Mitochondrial dysfunction has been implicated as a molecular mechanism for 
these clinical outcomes (Brinkman et al., 1999). Mitochondrial protein maintenance plays a critical 
role in retarding the development of NRTI-associated adverse health outcomes. Presently, only one 
study has quantified Lon expression in relation to antiretroviral use and lipodystrophy (Pinti et al., 
2010), however the response of SIRT3 and Lon in NRTI-induced hepatotoxicity has not been 
described. We previously showed that the NRTIs Zidovudine (AZT) and Tenofovir (TFV) induced 
acute oxidative stress in human hepatoma (HepG2) cells, while Stavudine (d4T) and TFV elevated 
oxidative stress markers following prolonged exposure (Nagiah et al., 2015). This was accompanied 
by a heightened antioxidant response. We replicated this model to assess the role of Lon and SIRT3 in 
the mt protein homeostatic response in HepG2 cells following acute [24 hour (h)] and prolonged (120 
h) exposure to NRTIs: AZT, d4T and TFV. 
Methods 
Cell culture and treatment 
Human hepatoma (HepG2) cells were cultured in 25cm3 cell culture flasks in Eagles minimum 
essential medium (Lonza; BioWhittaker, Johannesburg, South Africa) supplemented with 10%  foetal 
calf serum, 1% L-glutamine and 1% penstrepfungizone. Cells were allowed to reach 80% confluence 
prior to treatment. Stocks of antiretroviral drugs were made in DMSO (10mM). Cells were treated 
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with maximum plasma level concentrations (Venhoff et al., 2007; Walker et al., 2002) of AZT 
(7.1μM); d4T (4μM); and TFV (1.2μM). Antiretroviral drugs used were obtained from the NIH AIDS 
reagents program. Cells were exposed to NRTIs for 24 hours (h) and 120 h prior to harvesting for 
protein extraction. 
Protein preparation 
The protein expression of key proteins involved in mt protein homeostasis was assessed by the 
western blot technique. Treated cells were rinsed twice with 0.1M phosphate saline buffer (PBS) and 
incubated in 200μl Cytobuster reagent (Novagen, San Diego, CA) supplemented with protease and 
phosphatase inhibitors (Roche, Mannheim, Germany) for 10 minutes (min) on ice. The cell lysates 
were transferred to 1.5ml micro-centrifuge tubes and centrifuged (13,000 x g; 10 min). Crude protein 
extracts were aspirated and quantified using the bicinchoninic acid assay and standardized to 
1.2mg/ml. Proteins samples were then boiled in Laemelli buffer [dH2O, 0.5M Tris-HCl (pH 6.8), 
glycerol, 10% SDS, β-mercaptoethanol, 1% bromophenol blue] for 5 min. 
 
SDS-PAGE and Western blot 
The prepared protein samples were separated on SDS polyacrylamide gels (4% stacking, 7.5% 
resolving) by electrophoresis (150 V; 1 h). Separated proteins were transferred to nitrocellulose 
membranes using the TransBlot Turbo Transfer system (Bio-Rad, Hercules, CA, USA) at 400mA for 
45 min. Following transfer, nitrocellulose membranes were incubated in blocking solution (5% non-
fat dry milk; 1 h; RT) on a shaker. Membranes were then incubated in primary antibody (1:1000 
dilution in 5% non-fat dry milk) for 1 h, at RT on a shaker, followed by overnight incubation at 4ºC. 
Antibodies were obtained from Cell Signalling Technology (Beverly, MA, USA) and Sigma Aldrich 
(St Louis, MO, USA): anti-LONP1 (HPA002034), anti-HSP60 (D307), anti-SIRT3 (C73E3), anti-
phospho-eiF2α (Ser51; #3597), anti-phospho-JNK (Thr183/Tyr185; #9251). Following probing with 
primary antibody, membranes were rinsed (5 x 10 min) with Tween 20-Tris buffered saline (TTBS). 
The membranes were then incubated in horse radish peroxidase-conjugated secondary antibody (1: 
10,000 dilution in 5% non-fat dry milk) for 1 h, at RT on a shaker. The membranes were rinsed again 
(5 x 10 min) in TTBS prior to chemiluminescent detection. 
Protein bands were visualized using Clarity Western ECL detection reagent (Bio-Rad, Hercules, CA) 
and images were captured on the Alliance 2.7 gel documentation system (UviTech, Cambridge, UK).  
Densitometric analysis was done using the UviBand Analysis software (UviTech, Cambridge, UK). 
Protein expression was reported as relative band intensity (RBI) normalized against house-keeping 
protein β-Actin. Membranes were incubated in 5% hydrogen peroxide (37ºC) following detection of 
proteins to quench the bound secondary antibody. The membranes were then incubated with HRP-
conjugated anti-β-Actin (Sigma-Aldrich, St Louis, MO, USA) and rinsed prior to detection. The 





All experiments were conducted independently in triplicate. Statistical analyses were performed using 
the GraphPad Prism V5 software package (GraphPad Software, Inc., San Diego, CA, USA). All data 
sets were assessed for Gaussian distributions using the D’Agostino & Pearson omnibus normality test. 




Mitochondrial chaperone recruitment during NRTI toxicity 
The mt chaperones and proteases are required for mt maintenance. These proteins are recruited as part 
of the UPRmt and during ER stress. The major mt protein chaperone HSP60 was significantly 
increased by all three NRTIs evaluated at 24 h (AZT: 4.95±0.35RBI; d4T: 2.85±0.10RBI; TFV: 
4.99±0.18RBI) compared to the control (1.44±0.08RBI, Figure 4.1; p < 0.0001). This was also 
accompanied by a concurrent significant increase in Lon protein levels (AZT: 0.82±0.05RBI; d4T: 
0.93±0.02RBI; TFV: 0.85±0.01RBI) relative to the untreated cells (0.77±0.002RBI; Figure 4.1; p < 
0.001). Prolonged exposure to NRTIs caused a change in the recruitment of these proteins. The ATP 
dependent Lon and HSP60 proteins were significantly depleted at 120 h (Figure 4.2, p <0.0001). 
 
SIRT3 induction in NRTI treated HepG2 cells 
Sirtuin 3 is a NAD+ dependent mt deacetylase. The deacetylation of mt proteins is important in post-
translation regulation. This function has made SIRT3 central to the antioxidant response and UPRmt. 
Proteomic assessment of SIRT3 in HepG2 cells treated with NRTIs showed that the thymidine 
analogues - AZT and d4T significantly elevated SIRT3 at both 24 h (AZT: 0.64±0.01RBI; d4T: 
0.57±0.03RBI; Figure 4.1) and 120 h (AZT: 1.08±0.04RBI; d4T: 0.92±0.01RBI; Figure 4.2) relative 
to the control (24 h: 0.51±0.02RBI; 120 h: 0.85±0.02RBI; p < 0.0001). Tenofovir significantly 
increased SIRT3 protein levels during the acute time period (0.74±0.004RBI), but this was not 




Figure 4.1: Relative band intensity reported as fold change relative to control and western blot 
images for protein expression of Lon, HSP60 and SIRT3 following acute (24 h) treatment with 
antiretroviral drugs. **p < 0.005 ***p < 0.0001 relative to control 
 
Figure 4.2: Protein expression reported as relative fold change and western blot images for Lon, 
HSP60 and SIRT3 following 120 h exposure to antiretroviral drugs. **p < 0.005; ***p < 0.0001 
relative to control 
Endoplasmic reticulum stress associated proteins 
Phosphorylated JNK (Thr183/Tyr185) and phosphorylated eiF2α were assessed as responses to ER 
stress. Phosphorylated JNK is a kinase known to activate eiF2α in the event of ER stress. In both time 
periods there are similar expression patterns in the two proteins in each NRTI treatment. Both proteins 
were significantly up-regulated following acute exposure to AZT (p-eiF2α: 1.01±0.03RBI; p-JNK: 
1.31±0.30RBI) and TFV (p-eiF2α: 0.94±0.09RBI, p-JNK: 0.79±0.07RBI) compared to the untreated 
control (p-eiF2α: 053±0.02; p < 0.0001; p-JNK: 0.46±0.002RBI; p = 0.0003; Figure 4.3). At 120 h a 
significant depletion in p-eiF2α (0.78±0.02RBI; p =0.001) and p-JNK (0.51±0.05RBI; p = 0.003) was 
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observed in the TFV treated HepG2 cells (Figure 4.4). There was also a significant decrease of p-JNK 
induced by d4T (0.54±0.02RBI) in this time period relative to the control (1.27±0.40RBI). 
 
Figure 4.3: Densitometric analysis and western blot images of endoplasmic reticulum stress 
associated proteins in HepG2 cells following 24 h exposure to antiretroviral drugs. Results are 
normalized against β-Actin and reported as relative fold change. **p < 0.005; ***p < 0.0001 
relative to control 
 
Figure 4.4: Protein expression of endoplasmic reticulum stress associated proteins in HepG2 
cells reported as fold change following 120 h exposure to antiretroviral drugs. **p < 0.005 
relative to control 
Discussion 
Proteins have unique three-dimensional structures that are essential for their specific functions. 
Aerobic metabolism by cells constantly exposes the cells to various oxidizing species that can change 
the native structure of proteins. The accumulation of cross-linked protein aggregates and the inability 
of cells to remove protein occlusions eventually become toxic to the cell (Ngo et al., 2013). 
Mitochondria are protein dense and high traffic organelles exposed to high levels of oxidants. The 
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reduced capacity to maintain mt function by proteolytic clearance of protein aggregates may be a 
contributor to metabolic and age-related disorders. 
Lipodystrophy, metabolic syndrome and age-associated disorders are common health outcomes with 
NRTI use (Carr and Cooper, 2000; Smith et al., 2012). Mitochondrial toxicity is an underlying 
mechanism in all of these adverse drug reactions. Lon and SIRT3 are key components in the UPRmt. 
Compromised UPRmt with long term use of NRTIs may be a potential mechanism of toxicity and thus 
we investigated the proteins involved in UPRmt in relation to acute and chronic oxidative stress 
induced by NRTIs in HepG2 cells. 
The relationship between antiretroviral associated lipodystrophy and Lon was first described by Pinti 
et al. (Pinti et al., 2010). Adipose tissue from patients with lipodystrophy on antiretroviral therapy had 
significantly elevated gene expression of LONP1. It was established in a liposarcoma cell line that 
Lon expression was highest in d4T treated cells in response to oxidative stress. To date, this was the 
only study that evaluated Lon and antiretroviral toxicity. Using a hepatic in vitro model, we show Lon 
induction as an acute response to oxidative stress induced by NRTIs (Figure 4.1). This response was 
not observed in chronic exposure to NRTIs (Figure 4.2). Our data is consistent with that of Pinti et al. 
as d4T elicited the highest Lon expression at 24 h. Ngo. et al reported Lon as an acute stress response 
protein, while chronic stress results in dysregulation of Lon (Ngo et al., 2013). This dysregulation is 
associated with accelerated aging and associated disorders. We hypothesized that Lon, being an ATP 
dependent protease, could not be sustained over chronic oxidative stress periods resulting in 
progressive mt failure. In our previous study we showed severe depletion of ATP by the three NRTIs 
at 120 h. This depleted ATP level strongly correlates with significantly decreased Lon protein levels 
at 120 h (Figure 4.3). This suggests that continuous proteolytic activity may be detrimental to the cell 
over a long period of time. 
Another indication of ATP availability influencing stress responses is the decrease in HSP60 protein 
expression at 120 h (Figure 4.3). HSP60 is located in the mt matrix and is one of the most important 
mt chaperones. It is responsible for the transport of linear proteins from the cytoplasm to the mt 
matrix and refolding of imported mt proteins (Bukau and Horwich, 1998). The stability of HSP60 has 
been associated with steady Lon expression (Kao et al., 2015). We observed Lon and HSP60 protein 
profiles were similar in NRTI treated HepG2 cells, with increased expression in the acute treatment 
(Figure 4.1) and significant reduction in the prolonged treatment (Figure 4.2). This further establishes 
the interaction of Lon and HSP60 in acute stress response. 
Both Lon and HSP60 have been reported to be recruited as part of the transmission of ER stress to the 
mitochondria (Hori et al., 2002). We quantified protein expression of p-eIF2α (Ser51) as an indicator 
of ER stress. The activation of this protein by phosphorylation results in the repression of translation. 
The involvement of eIF2α as an ER response to mt damage has previously been reported (Baker et al., 
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2012). We observed that p-JNK (an activator of p-eIF2α) and p-eIF2α were significantly elevated 
during acute exposure to NRTIs (Figure 4.3). This indicates an elevation in misfolded proteins, 
initiating the ER stress response and induction of Lon expression. Aside from the translational 
repression elicited by eIF2α, activated JNK regulates co-translational degradation (Gandin et al., 
2010). While these responses may be beneficial during acute toxicity, chronic stress requires the 
initiation of repair and antioxidant responses (Nagiah et al., 2015). Therefore, translational repression 
cannot be sustained during chronic oxidative stress induced by NRTIs. This is observed in the 
significant decline in both protein levels at 120 h in all treated HepG2 samples (Figure 4.4). This 
down-regulation of ER stress response proteins also reduces stress transmission between the ER and 
mitochondria, reducing Lon and HSP60 activity. 
We observed SIRT3 protein expression was elevated by NRTIs in HepG2 cells at both time periods 
(Figure 4.1, 4.2). SIRT3 is NAD+ dependent, thus the depletion of ATP associated with sustained mt 
toxicity does not impact as severely on SIRT3 expression. Loss of SIRT3 expression is associated 
with aging (McDonnell et al., 2015) and metabolic disorders (Hirschey et al., 2010). The role of 
SIRT3 in mt metabolism, mt biogenesis (Kong et al., 2010), antioxidant defence (Qiu et al., 2010) and 
UPRmt (Papa and Germain, 2014) make this protein extremely relevant in mt disorders. The protective 
role of SIRT3 in mt integrity during chronic stress has previously been reported (Kim et al., 2010). 
Due to the multiple protective pathways that SIRT3 regulates, it can be expected that this protein is 
involved in stress responses to NRTI toxicity. Our previous work reported increased protein 
expression of downstream targets of SIRT3 involved in mt biogenesis (PGC-1α) and antioxidant 
(SOD1) in the same model (Nagiah et al., 2015). This indicates that SIRT3 provides protection 
against acute and chronic oxidative stress in NRTI treated hepatocytes. 
In conclusion, Lon mediated UPRmt is only relevant to acute toxicity but cannot be sustained due to 
high energy demand. SIRT3, on the other hand, regulates mt biogenesis, antioxidant defence and 
UPRmt. Also SIRT3 as a key component in chronic stress response to NRTI induced mt toxicity and 
oxidative stress, particularly in the AZT and d4T treated cells. Lon and HSP60 protein expression 
profiles are similar in NRTI induced stress response, possibly due to their functional interaction.  
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The ATP-binding cassette (ABC) super-family of drug transporters regulates efflux of xenobiotic 
compounds. The subfamily, multi-drug resistance proteins (MRPs) transports cyclic nucleotides and 
xenobiotics. Epigenetic modulation of drug transporters is scarcely described. The regulatory role of 
microRNA (miR)-124a on drug transporter gene ABCC4 was only recently reported. Our study 
investigated the differential regulation of miR-124a by nucleoside reverse transcriptase inhibitors 
(NRTIs): Zidovudine (AZT), Stavudine (d4T) and Tenofovir (TFV); at 24 h and 120 h treatments in 
HepG2 cells. ABCC4 mRNA (qPCR) and ABCC4 protein (western blot) were quantified. 
Cytotoxicity was evaluated by lactate dehydrogenase (LDH) levels. All NRTIs elevated miR-124a 
levels at 24 h, with a concomitant decline in ABCC4 mRNA levels (p<0.05). At 120 h, d4T and TFV 
elevated miR-124a and depleted ABCC4 mRNA levels (p<0.0001), while the inverse was observed 
with AZT (p<0.005). ABCC4 protein was increased by d4T and TFV at 24h. A significant reduction 
in protein levels was observed at 120 h in all three treatments (p<0.005). The disjoint in mRNA and 
protein levels is likely due to ABCC4 being a membrane bound protein. Following prolonged 
exposure, membrane integrity was compromised as evidenced by increased LDH leakage (p<0.005). 





The balance between drug toxicity and drug resistance depends on the absorption, distribution, 
metabolism and excretion (ADME) of xenobiotics. This is determined by the activity of drug 
metabolising enzymes and cellular drug transporters. Variability of ADME in different organs will 
either result in enhanced or limited drug exposure. Past studies on drug toxicology focussed on the 
metabolism of drugs (phase I and II) and consequent production of free radicals. However, phase III, 
which involves the energy dependent export of both non-metabolized and metabolized xenobiotics, 
has recently gained attention for its role in both drug resistance and cellular detoxification (Xu, et. al. 
2005; Doring and Petzinger, 2014). 
Cellular detoxification at drug deposition organs, such as the liver and kidney, is mediated by 
complex drug transporter systems. The super-family of ATP-binding cassette (ABC) drug transporters 
are responsible for the energy dependent efflux of endogenous and xenobiotic compounds. The ABC 
family of genes is divided into seven families (ABCA, ABCB, ABCC, ABCD, ABCE, ABCF, ABCG) 
with each sub-group exhibiting varying tissue and substrate specificity (Russell, et al. 2008). The 
ABCC class of genes code for membrane bound multi-drug resistance proteins. Five isoforms of 
ABCC (1-5) proteins are clinically relevant in the development of adverse drug reactions and drug 
resistance. The spectrum of ABCC substrates is diverse, including prostaglandins (Reid et al., 2003), 
bile salts and conjugates, steroids (Zelcer et al., 2003), reduced glutathione (Rius et al., 2003), cyclic 
nucleotides (Wielinga et al., 2003), antiviral drugs:- Tenofovir (TFV) and adefovir (Imaoka et al., 
2007), antihypertensive drugs:- furosemide and hydrochlorothiazide (Hasegawa et al., 2007), and 
anticancer drugs:- camptothecin (Tian et al., 2005), methotrexate (Chen et al., 2002), and topotecan 
(Tian et al., 2006). The unique ability of ABCC proteins, particularly ABCC4, to transport both cyclic 
nucleotides and antiretroviral drugs is of importance for the efficacy and toxicity of nucleoside 
analogues used in anti-HIV treatment. 
The functionality and expression of ABCC4 is highly variable. Genetic polymorphisms in the ABCC4 
gene and stress activators may play a role in the expression of ABCC4 protein, but this has not been 
consistent across different human populations (Abla et al., 2008, Chai et al., 2011, Xu et al., 2010, 
Maher et al., 2007, Mentzel et al., 2015). Epigenetic modifications scarcely describe a mechanism in 
the modulation of cellular drug transport (Ivanov et al., 2014). This form of gene regulation refers to 
heritable changes in gene expression independent of modifications to the DNA sequence or genotype 
variation. Mechanisms of epigenetic gene regulation include DNA methylation, histone and chromatin 
modification, and microRNAs (miRNA). 
MiRNAs are small non-coding RNA molecules (18-25 nucleotides) involved in post translational 
gene silencing. The negative regulation of gene expression is achieved by inclusion of miRNA in an 
RNA-induced silencing complex (RISC) via complementary base pairing to target genes. 
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Incorporation into RISC results in either destabilisation of the mRNA by shortening of the poly A tail, 
strand cleavage, or translational repression (Markova and Kroetz, 2014). MiRNAs have multiple 
targets, including genes involved in drug metabolism and excretion (Yu, 2009).  
Changes to miRNA levels in the presence of antiretroviral drugs will have implications for ABCC4 
targets, thus influencing bio-accumulation and toxicity. There is limited information on the 
differential regulation of miRNA by antiretroviral drugs and subsequently, pharmacokinetic changes. 
A recent study reported direct regulation of ABCC4 by miR-124a in human embryonic kidney cells 
(Markova and Kroetz, 2014). The mechanism of ABCC4 modulation, however, has not been 
investigated in liver cells, or in relation to antiretroviral drug exposure. Although miR-124a is 
predominantly expressed in blood, brain and renal cells, this miRNA has recently been shown to be 
expressed in pig liver (Mentzel et al., 2015) The regulatory role of miR-124a in the liver (HepG2 
cells) was further reiterated in an in vitro study by Phulukdaree et. al (2015). The study 
showed inhibition of miR-124a caused an increase in the mRNA and protein expression of 
miR-124a target GAMT (Phulukdaree et al., 2015). Clearly, there is an emerging role for 
miR-124a in hepatic stress response. 
 We evaluated the effect of three antiretroviral drugs of the nucleoside reverse transcriptase inhibitor 
(NRTI) class on ABCC4 and ABCC4 expression in human hepatoma (HepG2) cells. These drugs are 
functional analogues of native nucleotides but lack the 3’- hydroxyl group on the sugar moiety. 
Chronic exposure to these drugs have been associated with changes to metabolism, mitochondrial 
dysfunction and hepatic steatosis (Brinkman et al., 1998, Begriche et al., 2011). In the present study 
we investigated differential regulation of miR-124a induced by NRTIs in two time periods (24 h; 120 
h) and the subsequent effect on ABCC4 mRNA levels and ABCC4 protein expression. 
Methodology 
Materials 
All materials were purchased from Merck (Darmstadt, Germany) unless otherwise stated. Antibodies 
used in western blot protein detection were purchased from Cell Signalling Technology Inc (Beverly, 
MA, USA). Cell culture medium was obtained from Lonza BioWhittaker (Johannesburg, South 
Africa) and supplements were obtained from Sigma-Aldrich (St Louis, MO, USA). Antiretroviral 
drugs were donated as part of the NIH AIDS program. 
 Treatment 
HepG2 cells (1.5x106) were seeded in 25cm3 sterile cell culture flasks and maintained in cell culture 
medium (10% foetal calf serum, 1% L-glutamine, 1% penstrepfungizone) at 37°C, 5% CO2. Once 
cells had reached 70%-80% confluence, treatments were administered. NRTI stock solutions (10mM) 
82 
 
were made up in dimethyl sulfoxide. Cells were treated with maximum plasma level concentrations of 
NRTIs (Venhoff et al., 2007, Walker et al., 2002): AZT (7.1μM), d4T (4μM) and TFV (1.2μM); for 
24 h and 120 h. For the prolonged treatment, cells were rinsed with 0.1M phosphate saline buffer 
(PBS) and replenished with fresh media containing the treatment. 
 Cytotoxicity assay 
 The lactate dehydrogenase (LDH) cytotoxicity detection kit (Roche, Mannheim, Germany) was used 
to measure the cell damage and cytotoxicity in NRTI treated HepG2 cells. Extracellular LDH activity 
was quantified by incubating 100µl of cell culture supernatant with 100µl substrate solution 
(diaphorase/NAD+; INT/sodium lactate) in a 96-well microtitre plate at room temperature for 30 
minutes. The assay was performed with six technical replicates. Optical density (OD) was measured 
following incubation at 500nm using a spectrophotometric plate reader (Bio-Tek uQuant, Winooski, 
VT, USA). 
RNA isolation and mi-RNA expression 
Following treatment, cells were rinsed with 0.1M PBS. Thereafter, 500μl of QIAzol Lysis Reagent 
(Qiagen, Maryland, USA) were added to each cell culture flask. Total RNA was isolated by an in 
house protocol based on isopropanol precipitation as described by Chuturgoon et al. (Chuturgoon et 
al., 2014). Total RNA was quantified using the Nanodrop 2000 spectrophotometer (ThermoScientific, 
South Africa) and standardized to 2000ng/μl in nuclease free water. Standardized RNA samples were 
then converted to complementary DNA (cDNA) using the miScript II RT kit (Qiagen, Maryland, 
USA). MiR-124a expression was analysed using the miScript SYBR Green PCR kit (Qiagen, Catalog 
no. 218073) according to the manufacturer’s instructions. An internal control (RNU6B), was used as a 
reference control gene to normalize miR-124a expression. . 
ABCC4 mRNA expression 
Isolated RNA was converted to cDNA by the iScriptTM cDNA Synthesis kit (BioRad; catalog no. 107-
8890) as per the manufacturer’s instructions. A reaction volume of 20µl containing 5X iScript 
reaction mix, 1µl of iScript reverse transcriptase and 2,000ng of RNA template were made up in 
nuclease free water. Thermocycler conditions for cDNA synthesis were 25°C for 5 min, 42°C for 30 
min, 85°C for 5 min and a final hold at 4°C. The levels of ABCC4 mRNA were quantified using the 
iQTM SYBR® Green Supermix (BioRad, 170-880). A reaction volume of 25μl consisting of 1µM of 
sense primer (5’-CGATGAGCCATGTGCCATATGA-3’), 1μM antisense primer (5’-
TTGACTATCTATCTGGCCTGTGGTTGT-3’), 5X iScript reaction mix and nuclease free water 
were subject to thermocycler conditions. Initial denaturation was conducted at 95°C for 4 min, 
followed by 37 cycles of denaturation (95°C; 15 sec), annealing (58°C ; 40 sec), and extension (72°C; 
30 sec). An internal control (GAPDH) was also run simultaneously. 
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All qPCR experiments were conducted on the CFX96 TouchTM Real-Time PCR Detection System 
(BioRad, Hercules, CA, USA). Changes to gene expression were calculated according to the methods 
described by Livak  and Schmittgen (Livak, 2001). Results are converted from mean relative fold 
change (2-∆∆Ct) to percentage mRNA expression relative to the untreated control (100%).  
Relative protein quantification of ABCC4 
Relative quantification of ABCC4 protein was done using western blotting. Crude protein was 
extracted from HepG2 cells following treatment with NRTIs. Cells were rinsed twice with 0.1M PBS. 
Thereafter, 200μl of Cytobuster (Novagen, San Diego, CA, USA) supplemented with protease and 
phosphotase inhibitors (Roche, Mannheim, Germany), was added to cell culture flasks. Flasks were 
placed on ice (30 min) prior to cells being scraped and transferred to 1.5ml sterile tubes. Lysates were 
centrifuged (13,000 g, 10 min), allowing aspiration of the crude protein supernatant. Crude protein 
quantification was carried out via the bicinchoninic assay. Protein samples were standardized to 
1mg/ml and boiled in Laemmeli buffer [dH2O, 0.5M Tris-HCl (pH 6.8), glycerol, 10% SDS, β-
mercaptoethanol, 1% bromophenol blue] for 5 min. 
SDS polyacrylamide gel electrophoresis (4% stacking gel, 10% resolving gel; 1 h; 150 V) was applied 
to separate protein samples according to molecular weight. The separated proteins were blotted on to 
nitrocellulose using the TransBlot Turbo Transfer System (BioRad, Hercules, CA, USA) at 400mA 
for 45 min. Following transfer, the nitrocellulose membrane was incubated in blocking solution [5% 
non-fat dry milk in Tween 20-Tris buffered saline (TTBS)] for 1 h on a shaker. The membrane was 
probed with rabbit anti-ABCC4 of 1:500 dilution (cat no. D1Z3W, Cell Signalling Technology, 
Beverly, MA, USA) for 1 h at room temperature, prior to overnight incubation at 4°C. Following 
probing with primary antibody, membranes were rinsed 5 times (10 min) in TTBS. Membranes were 
incubated in HRP-conjugated goat anti-rabbit (ab6112; 1:5,000 dilution) for 1 h at room temperature. 
This was followed by 5 rinses with TTBS. Clarity Western ECL Substrate (BioRad, Hercules, CA, 
USA) detection reagent was used to visualise protein bands. Images were captured using gel 
documentation system Alliance 2.7 (UviTech, Cambridge, UK). Relative band density (RBI) was 
measured by densitometric analysis using UviTech Alliance Analysis software (Cambridge, UK). 
Membranes were incubated in 5% hydrogen peroxide to quench the chemiluminescent signal. The 
membranes were then probed with a house keeping protein [β-actin (Sigma, St Louis, MO, USA)/] to 
normalize the results. Results are reported as percentage change relative to control (100%) 
Statistical analysis 
Statistical analyses were performed using the GraphPad Prism V5 software package (GraphPad 
Software Inc., San Diego, CA, USA). All experiments were carried out in triplicate unless otherwise 
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stated. Comparisons between the control and drug treatments were done by performing one-way 
analysis of variance (ANOVA). Statistical significance was accepted at p value < 0.05. 
Results 
MiR-124a levels 
Levels of miR-124a were increased in all NRTI treatments at 24 h, with a significant increase in the 
TFV treated HepG2 cells (Figure 5.1A; p = 0.0009). Following prolonged exposure, d4T and TFV 
sustained elevated miR-124a levels relative to the control (Figure 5.1B; p < 0.0001). However, miR-
124a levels of the AZT treatment in this time period were reduced to 26.25% of the untreated control 
(p  = 0.02). 
 
Figure 5.1: Quantitative PCR analysis of miR-124a levels in HepG2 cells following exposure to 
antiretroviral drugs or 24 h (A) and 120 h (B). MicroRNA-124a levels are expressed in 
percentage (%) relative to control (100%; *p < 0.05, ***p < 0.001 relative to control) 
ABBC4 mRNA levels 
MiR-124a results in degradation of target gene ABCC4 by complementary base pairing, thus lowering 
ABCC4 mRNA levels. Evaluation of ABCC4 mRNA levels in HepG2 cells following acute and 
prolonged exposure showed that NRTIs caused a significant decline in ABCC4 mRNA levels at 24 h, 
with the lowest levels observed in the TFV (9.34%) and d4T (5.59%)  treated cells (Figure 5.2A; p < 
0.0001). The 120 h results showed d4T and TFV treated HepG2 cells had consistently low ABCC4 
mRNA (Figure 2B), which corresponded with the elevated miR-124a levels (Figure 5.1A). The AZT 
treatment, however, increased ABCC4 mRNA levels (Figure 5.2B, p = 0.003), with a corresponding 




Figure 5.2: Quantitative PCR analysis of ABBC4 mRNA levels at 24 h (A) and 120 h (B) in 
HepG2 treated with antiretroviral drugs. ABBC4 mRNA is represented as a percentage relative 
to untreated control (*p < 0.05; ***p < 0.0001 relative to control) 
 
 Relative ABCC4 protein quantification 
Densitometric analysis of ABCC4 western blot images showed no change in the AZT treated cells at 
24 h. In the same time period, TFV and d4T significantly increased ABCC4 protein expression 
(Figure 5.3A; p = 0.005). At 120 h all three NRTIs caused a significant decline in ABCC4 protein 
expression (Figure 5.3B; p < 0.0001). 
 
Figure 5.3: Densitometric analysis of western blot for ABCC4 protein at 24 h (A) and 120 h (B) 







Extracellular LDH was quantified as a measure of cytotoxicity. All NRTIs significant increased 
extracellular LDH activity at both time periods (Figure 5.4; p < 0.001). 
 
Figure 5.4: Extracellular LDH levels used as an indicator of cytotoxicity was significantly 
increased in NRTI treated cells at both 24 h (A) and 120 h (B); ***p < 0.0001 relative to control 
Discussion 
The long term use of antiretroviral therapy has seen the emergence of an “epidemic within an 
epidemic”. Although the morbidity and mortality of HIV infection improved since the advent of 
antiretroviral therapy, long term side effects (metabolic syndrome, lipodystrophy, hepatic steatosis), 
have reduced the quality of life of patients (Brinkman et al., 1998). Pharmacokinetic properties of 
drugs are imperative to understanding mechanisms of drug toxicity. Detoxification pathways in 
particular have physiological relevance in determining possible adverse drug reactions. 
There is limited information on the role of epigenetic mechanisms in drug transport and excretion, 
especially for chronic drug usage.  Recent advancements in this field, however, show miRNA as key 
components in drug transport (Smith et al., 2012). Borel et. al (2012) showed the involvement of 13 
miRNAs that targeted ABC transporters: ABCC1, ABCC5, ABCA1, ABCC10, ABCE1 in 
hepatocellular carcinoma (Borel et al., 2012). ABCA1 is regulated by miR-33 and miR-758 (Ramirez 
et al., 2011). Breast cancer resistance protein, ABCG2, is regulated by hsa-miR-328; -519c; -520h (Li 
et al., 2011). Markova and Kroetz (2012) showed a regulatory mechanism between miR-124a and 
ABCC4 in human embryonic kidney cells (Markova and Kroetz, 2014). Using this study, we 
investigated the effect of miR-124a on ABCC4 mRNA and ABCC4 protein in HepG2 cells treated 
with NRTIs. ABCC4 is of significance to NRTI detoxification due to its unique ability to transport 
both metabolized drugs and cyclic nucleotides (Wielinga et al., 2003). The varying effects of different 
NRTIs on miR-124a and ABCC4 is likely to have consequences for hepatic clearance. 
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Complementary base pairing between the miR-124a seed region and the target sequence of ABCC4 
facilitate binding of RISC to the 3’-UTR of ABCC4. This binding results in disruption to the putative 
binding site on the ABCC4 gene, causing mRNA degradation (Markova and Kroetz, 2014). Our study 
showed that miR-124a was elevated by d4T and TFV at both 24 h and 120 h (Figure 5.1), with 
concomitant repression of ABCC4 mRNA (Figure 5.2). The inverse relationship between miR-124a 
and ABCC4 was further reiterated in AZT treated HepG2 cells, where an increase in miR-124a was 
accompanied by reduced ABCC4 mRNA levels at 24 h, while the inverse was applicable at 120 h. The 
reduced mRNA levels of ABCC4 did not correlate with ABCC4 protein expression at 24 h in the 
NRTI treated cells. 
ABCC4 regulates cellular detoxification, thereby reducing cytotoxicity. At 24 h, d4T had the lowest 
LDH extracellular activity relative to AZT and TFV treated cells in the same time period (Figure 
5.4A). This treatment also corresponds with the highest ABCC4 protein levels at 24 h (Figure 5.3A). 
Previously, our investigation on mitochondrial and oxidative stress (using the same experimental 
model)  showed d4T exhibited little or no toxicity at 24 h (Nagiah et al., 2015). The elevated levels of 
ABCC4 protein may have contributed to lower cytotoxicity as compared to AZT and TFV. At 120 h, 
however, we observed severe depletion of ABCC4 protein levels in all NRTI treatments (Figure 
5.3B). This was corroborated by the elevated levels of LDH activity at 120 h (Figure 5.2B), 
suggesting increased cell damage. Our previous work on mitochondrial toxicity also showed 
heightened toxicity, particularly in the d4T and TFV treatments, at 120 h (Nagiah et al., 2015). 
Although TFV displayed elevated LDH levels at 120 h compared to the control, it appears the 
cytotoxicity begins to decline compared to the acute treatment. Reasoning for this observation may be 
due to TFV eliciting a high antioxidant response at chronic exposure and maintaining mitochondrial 
DNA levels, promoting cell functionality (Nagiah et al., 2015). 
The reduced capacity for cellular clearance of drugs and their metabolites may contribute to cytotoxic 
events. Over-expression of ABCC4 has been shown to confer resistance to acetaminophen induced 
hepatotoxicity (Aleksunes et al., 2008). Another study showed ABCC4 suppression caused an 
elevation in intracellular levels of bio-transformed AZT and the antiretroviral agent lamivudine 
(Anderson et al., 2006). We observed a decrease in ABCC4 protein expression at 120 h in NRTI 
treated cells, which reduces the detoxification capacity of the cell. The significant decline in ABCC4 
protein levels at 120 h can be due to loss of cellular membrane integrity. Our previous work showed 
significant elevation of extracellular malondialdehyde, a by-product of lipid peroxidation, following 
prolonged exposure to NRTIs (Nagiah et al., 2015). Reactive oxygen species are produced during 
drug metabolism, and are capable of reacting with cell membranes, generating lipid peroxides (Bort et 
al., 1999). The exacerbated oxidative stress in this time period would result in the progressive decline 
in cell membrane integrity, reducing the levels of membrane bound protein ABCC4. .  
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Other possible reasons for the discrepancy in ABCC4 mRNA levels and ABCC4 protein could be 
reduced ATP availability and compromised protein assembly. Previously we showed that ATP levels 
were unaffected at 24 h by d4T and a slight decline in the AZT and TFV treated cells, however, at 120 
h there was severe depletion of ATP by all three drugs due to NRTI mitochondrial toxicity (Nagiah et 
al., 2015). ABCC4 is an ATP-dependent protein and depleted levels of ATP will reduce its activity. 
Furthermore, the prolonged exposure to NRTIs exacerbates oxidative stress. Oxidative stress causes 
an accumulation in misfolded proteins and compromises post translational processing of proteins in 
the endoplasmic reticulum (Phulukdaree et al., 2015). Thus ABCC4 mRNA is present, but the 
machinery for processing functional ABCC4 protein may be compromised due to the unfavourable 
oxidative environment. 
Translational regulation of ABCC4 has been previously described (Xu et al., 2010). Activator of 
ABCC4 protein expression, nuclear erythroid factor 2 related factor 2 (Nrf2) was recently evaluated in 
our laboratory in the same model. This transcription factor was significantly increased by all three 
NRTIs at 120 h. In spite of elevation of this ABCC4 activator, protein levels were still significantly 
lower in this time period. Hence, we can deduce that cell membrane integrity and ATP availability 
over-ride translational regulation of ABBC4 under prolonged oxidative stress (Nagiah et al., 2015). 
In conclusion, the antiretroviral drugs AZT, d4T and TFV differentially regulates miR-124a and 
influences ABCC4 gene expression. Prolonged exposure to NRTIs compromises drug export by 
reducing ABCC4 protein expression, thus contributing to reduced cellular clearance and increased 
drug toxicity. MiR-124a may influence hepatic clearance of d4T and TFV, thereby reducing hepatic 
toxicity. Although miR-124a directly regulates ABCC4 mRNA expression, ABCC4 protein 
expression is dependent on other factors such as ATP availability and oxidative status of the cell. 
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Metabolic syndrome, lipodystrophy, and liver toxicity are common outcomes with long term use of 
HAART. Nucleoside reverse transcriptase inhibitors, the cornerstone of HAART, are known inducers 
of mt toxicity. The mechanism by which NRTIs exert mt toxicity is still debatable as the depletion of 
mtDNA is not consistent in all NRTIs. Furthermore, NRTIs display tissue specific toxicity: d4T – 
hepatic, adipose (Saint-Marc, Partisani et al. 1999, Setzer, Lebrecht et al. 2008); AZT – hepatic, 
cardiac, peripheral muscle (Barile, Valenti et al. 1997, Benbrik, Chariot et al. 1997, de la Asunción, 
del Olmo et al. 2004); TFV – renal (Abraham, Ramamoorthy et al. 2013). 
The liver is of particular importance in relation to drug toxicity as it is central to xenobiotic 
metabolism. The liver is at high risk for both oxidative insult due to drug metabolism and drug 
deposition. Mitochondrial toxicity and oxidative stress are common in NRTI toxicity with each NRTI 
having differing degrees of toxicity. Understanding the molecular aetiology of NRTI induced liver 
toxicity may aid in the clinical management of HIV-therapy. We selected three of the most commonly 
used NRTIs (AZT, d4T, TFV)  used in fixed dose combinations in developing countries (Simbayi, 
Shisana et al. 2014). This in vitro study was designed to represent both acute and prolonged exposure 
to NRTIs in order to evaluate changes in stress response profiles. 
Both AZT and TFV compromised ATP production and elevated biomarkers for oxidative stress at 24 
h. Stavudine only induced oxidative stress and mt dysfunction following prolonged exposure, 
surpassing the toxicity of AZT and TFV at 120 h. This was accompanied by a significant reduction in 
mtDNA content (36.1%). Tenofovir was also toxic to mt as observed by both reduced ATP levels and 
mt membrane polarisation, but this was independent of mtDNA depletion. These findings show that 
although mtDNA depletion may exacerbate the mt toxicity observed with d4T and AZT, this was not 
the mechanism of NRTI-associated mt toxicity. 
In the assessment of the endogenous HepG2 antioxidant response, TFV induced the highest Nrf2 and 
SOD1 expression (>2 fold), as well as the DNA repair mechanism, OGG1. Although TFV disrupted 
cellular energy status, the heightened induction of Nrf2 mediated antioxidant response may explain 
why TFV is considered less toxic than d4T and AZT in a clinical setting. Further, Nrf2 and its 
downstream target, SOD1, were markedly elevated after prolonged exposure to NRTIs and strongly 
suggests that Nrf2 is required for chronic stress response to NRTIs. 
Another important stress response to mt toxicity is the regulator of mt biogenesis, PGC-1α; PGC-1α 
was significantly increased following acute and prolonged exposure to NRTIs in HepG2 cells. 
Besides its role in mt biogenesis, PGC-1α also induces a battery of antioxidant responses in the 
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mitochondrion to mt toxicity. The transcription factor -TFAM, responsible for transcribing mtDNA, 
was only increased after prolonged exposure to NRTIs, indicating this may be a late response. 
The NRTI depletion of ATP in HepG2 cells at 120 h reduced ATP-dependent stress responses that 
regulate mt protein homeostasis.  As a result, Lon protease and the associated protein maintenance 
proteins were elevated after acute NRTI exposure, but was not sustained over prolonged exposure. 
The dysfunction of Lon due to chronic oxidative stress is associated with age-associated disorders, a 
characteristic of chronic HAART use. The loss of Lon activity and the translational repressor, eIF2α, 
seems to promote mt biogenesis and mt antioxidant response. Lon selectively degrades TFAM, and 
during prolonged stress this may be detrimental to the cell. In order for mt biogenesis to be increased 
to compensate for mt toxicity, Lon activity needs to be reduced. Furthermore, translational repression 
by eIF2α will be problematic following prolonged exposure to NRTIs, as the processing of proteins 
involved in antioxidant response will need to be increased. Post-translational regulation of Lon by 
SIRT3 may be relevant, as an inverse relationship between these two mt matrix proteins in both time 
periods was observed. Sirtuin 3 is NAD+ dependent, and depleted ATP levels will not significantly 
impact on its functionality. Changes in energy and redox status induce SIRT3 activity, which down-
regulates Lon and increases mt antioxidant response. 
The ATP-binding cassette C4 (ABCC4) gene is responsible for the transport of xenobiotic molecules 
and endogenous nucleotides, making this membrane protein highly relevant for NRTI transport. The 
activity of this efflux protein determines intracellular drug concentration and facilitates cellular 
detoxification in the liver. The regulation of cellular drug transporters by miRNA is a potential target 
for enhancing hepatic drug clearance. The ABCC4 gene is directly regulated by miR-124a; a 
mechanism as yet to be described in relation to NRTI hepatic toxicity. The acute exposure to all three 
NRTIs significantly increased miR-124a levels (24h), with a concomitant decline in ABCC4 mRNA 
levels. A similar trend was observed following 120h exposure to d4T and TFV. After 120h exposure 
to AZT, miR-124a levels significantly decreased, while ABCC4 mRNA levels increased. Although a 
negative association between miR-124a and ABCC4 became apparent, this could not be correlated 
with protein expression of the ABCC4 gene (MRP4). A significant decrease in MRP4 was observed in 
all treatments at 120h, compromising the export of the NRTIs. Since MRP4 is a membrane bound 
protein, the loss of cell membrane integrity due to lipid peroxidation (as observed by elevated MDA 
content) can negatively impact protein expression. Furthermore, MRP4 requires ATP for its efflux 
activity and the decreased ATP levels (120h) to NRTIs will reduce MRP4 capacity. 
In conclusion the data shows that mt function and oxidative stress are induced by AZT, d4T and TFV, 
especially at 120h, in HepG2 cells. The consequent disruption of energy production has implications 
for long term stress responses, including those involved in protein maintenance and cellular 
detoxification. MicroRNA that target cellular detoxification proteins provide a potential therapeutic 
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intervention for NRTI-associated hepatic toxicity. Future studies still need to be done to validate the 
findings with use of inhibitors/mimics of the key regulators identified (Nrf2, Lon, miR-124a).  
Although this study offers insight to molecular events in the presence of acute and prolonged NRTI 
exposure in liver cells, there are limitations to the interpretation of the results reported. An in vitro 
model always poses the challenge of a unicellular model, thus not accounting for a systemic 
interactions in a multi-organ environment. Findings from this study, however, provide stepping stones 
to identifying molecular targets at the clinical level. The pathways investigated can be adapted to an 
in vivo model (animal study) to further refine molecular targets of NRTI toxicity. These findings can 
then be further investigated in patients exhibiting NRTI-associated adverse health outcomes such as 




APPENDIX A  
 
Apoptosis assessment (Caspase activity) 
In order to assess the induction of apoptosis (programmed cell death) in HepG2 cells following acute 
(24 h) and prolonged (120 h), caspase activity (8/9/3/7) was assessed using a luminometric assay. The 
Caspase-Glo® 8 Assay, Caspase-Glo® 9 Assay, Caspase-Glo® 3/7 Assay (Promega, Madison, USA) 
were conducted according to the manufacturer’s instructions. Briefly 20 000 cells (50µl in 0.1MPBS) 
were seeded in a 96-well white microtitre plate with 20µl reagent per replicate. Samples were mixed 
by agitation and incubated in the dark (RT; 30 min). Luminescent signal was detected on a 
ModulusTM Microplate Luminometer (Turner Biosystems, Sunnyvale, USA). Results are expressed as 
relative light units (RLU) and converted to fold change relative to the control. 






































Figure 1: Caspase activity following acute and prolonged exposure to NRTIs; *p < 0.05, **p 
<0.005, ***p < 0.0001 
Early marker for apoptosis, phosphatidyl-serine externalisation, was quantified by Annexin-V-Fluos 
staining and FACS. Briefly, 1 000 000 cells per treatment were reconstituted in 100µl 0.1MPBS and 
stained with 100μl of staining buffer, 100μl of Annexin-V-Fluos labelling solution (Annexin-V: 
propidium iodide (PI): staining buffer (1:1:50 vol/vol/vol)). Cells were incubated in staining solution 
in the dark (15 min; RT). Flow cytometry data from stained cells (50 000 events) was captured with 
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the Accuri™ C6 flow cytometer and software (BD Biosciences, San Jose, CA, USA). Live cells were 
gated using CFlow Plus Software (BD Biosciences, San Jose, CA, USA). Data is represented as 
percentage apoptotic cells. The results show only TFV elevated phosphatidyl-serine externalisation 
following acute exposure (Addendum A - Figure 2). At 120 h all NRTIs increased this early marker 
for apoptosis. 
 























Figure 2: Annexin-V-Fluos data for phosphatidyl-serine externalisation in HepG2 cells treated 





LonP1 gene expression 
LonP1 gene expression was quantified by qPCR. Isolated RNA was standardized to 1000ng/µl and 
converted to cDNA using the RT2 First Strand Kit as per the manufacturer’s instructions (Qiagen, 
Maryland, USA). A predesigned LonP1 Taqman® Gene Expression Assay (ThermoFischer Scientific, 
Waltham, MA, USA) was used to quantify LonP1 gene expression. The ViiaTM7 Real Time PCR 
system was used to conduct thermocycler conditions and capture gene expression data 
(ThermoFischer Scientific). 
 
Figure 1: LonP1 gene expression in HepG2 cells following 24 h (A) and 120 h (B) exposure to 





RNA isolation protocol 
The isolation of RNA from HepG2 cells was carried out using an in-house protocol. Following 
treatment, cells were rinsed thrice with 0.1M PBS. Thereafter, 500µl of QIAzol RNA extraction 
reagent (Qiagen) and 500µl of 0.1M PBS was added to each flask. Cells were incubated in QIAzol for 
5 min at RT. Cells were then mechanically lysed with a cell scraper and lysates were transferred to 
1.5ml microcentrifuge tubes and allowed to freeze overnight (-80ºC). Samples were thawed done 
following incubation and 100µl chloroform was added per sample. Samples were agitated for 15 s and 
allowed to stand for 3 min at RT. The samples were then centrifuged (15 min; 12 000 x g; 4ºC) and 
the aqueous phase was transferred to fresh microcentrifuge tubes. Isopropanol (250µl) was added to 
the aqueous phase and left on ice for 2 h before overnight incubation (-80ºC). Following incubation, 
samples were centrifuged (20 min; 12 000 x g; 4ºC). The supernatant was discarded and the pellet was 
rinsed with cold 75% ethanol (500µl). Samples were centrifuged (15 min; 7 400 x g, 4ºC) and the 
ethanol was discarded. The pellets were allowed to air dry prior to being reconstituted in 15µl of 
nuclease free water. The reconstituted RNA was allowed to stand at RT for 10 min to allow 





Protein expression (western blot) 
The following western blots were run to evaluate protein expression of p-SIRT1 (Addendum D- 
Figure 1), p-p53 (Addendum D – Figure 2), and SIRT5 (Addendum D –Figure 3) as pro-survival 
proteins during stress response. Sirtuin 1 is a cytosolic SIRT that has been implicated in biological 
aging. Both p53 and SIRT1 have been identified for interaction with Lon during cellular senescence. 
The transcription factor p53 is involved in cell death response and DNA damage response. Sirtuin 5 is 
located in the mitochondrion and plays a role in metabolism. 
 
























Figure 1: Densitometric analysis of phosphorylated SIRT1 protein expression in HepG2 cells. 
Data is reported as relative band intensity (RBI) normalized against β-Actin; *p < 0.05, **p 



























Figure 2: Densitometric analysis of phosphorylated p53 (Ser392) protein expression in HepG2 
cells. Data is reported as relative band intensity (RBI) normalized against β-Actin; *p < 0.05, 




Figure 3: Densitometric analysis of SIRT5 protein expression in HepG2 cells. Data is reported 




Intracellular ROS quantification by DCF staining 
Intracellular ROS was determined by flow cytometric analysis of DCF positively stained cells. At 
120h, all three NRTI treated cells had a higher percentage of DCF positive stained cells relative to the 
control (Addendum E - Figure 1). 
 
Figure 1: FACS analysis of DCF positive stained cells. At 24 h AZT (B) and TFV (D) had 
increased levels of intracellular ROS relative to the control (A). At 120 h, however, all three 
NRTIs had a higher percentage of DCF positive cells compared to the control (E), with TFV 
exhibiting the highest ROS levels (H) 
 
